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1. Introduction 
 
1.1 c-MYC oncogene 
c-MYC proto-oncogene was identified as the cellular homolog of the viral 
oncogene v-MYC encoded by the avian myelocytomatosis virus (Vennstrom et al., 
1982). c-MYC is a transcription factor which specifically binds to so-called E-boxes 
(CACGTG) and regulates expression of multiple genes involved in control of cell 
growth, proliferation, differentiation, apoptosis, angiogenesis, cellular adhesion, DNA 
metabolism and repair (Dang, 1999; Eisenman, 2001; Oster et al., 2002; Pelengaris et 
al., 2002a). 
Deregulation of c-MYC expression is observed in many human cancers and has 
been implicated in a number of cellular processes associated with tumorigenesis such 
as reduction of growth-factor requirements, immortalization, resistance to anti-
mitogenic signalling, increase of angiogenesis, changes in adhesion and genomic 
instability (Baudino et al., 2002; Lutz et al., 2002; Pelengaris et al., 2002b). The ability 
of c-MYC to induce unrestrained and autonomous cell growth and proliferation seems 
to be particularly important for tumorigenesis.  
c-MYC acts at different stages of cell cycle. c-MYC enforces transition through 
G1/S and prolongs the G2/M phase (Felsher and Bishop, 1999; Karn et al., 1989) and is 
able to overcome cell cycle arrest induced by DNA damage (Chernova et al., 1998; 
Sheen and Dickson, 2002). The effects of c-MYC on the cell cycle are mediated by 
transcriptional activation or repression of genes encoding cell cycle regulators (Daksis 
et al., 1994; Hermeking et al., 2000; Hoang et al., 1995; Yang et al., 2001; Yin et al., 
2001).  
One of the factors limiting c-MYC-dependent transformation and tumorigenesis 
is programmed cell death (apoptosis) (Meyer et al., 2006; Nilsson and Cleveland, 2003; 
Prendergast, 1999), which seems to be a cellular response to unscheduled proliferation 
and is mediated by p53 activation (Hermeking and Eick, 1994). The tumor suppressor 
p14arf mediates activation of p53 by c-MYC (Zindy et al., 1998). Furthermore, activation 
of c-MYC was shown to promote the release of cytochrom c from mitochondria, where 
it functions through activation of BAX (Mitchell et al., 2000; Soucie et al., 2001), 
induction of BIM (Egle et al., 2004) or repression of the anti-apoptotic BCL-XL and BcL2 
proteins (Eischen et al., 2001). More recently, activation of c-MYC was shown to induce 
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apoptosis via generation of DNA damage (Herold et al., 2002; Seoane et al., 2002; 
Sheen and Dickson, 2002). 
Genomic damage induced by c-MYC may involve a variety of different 
mechanisms including inappropriate cell cycle transition, perturbation of DNA 
replication, bypass of cellular check-points, suppression of DNA repair, induction of 
ROS production, chromosome and telomere remodeling (Chernova et al., 1998; 
Felsher and Bishop, 1999; Felsher et al., 2000; Karlsson et al., 2003; Li and Dang, 
1999; Mai et al., 1996b; Yin et al., 2001). c-MYC-induced genomic instability can be 
classified into two categories: abnormal chromosomal numbers (aneuploidy) and 
defects in chromosomal integrity including chromosomal breaks, fusions and 
translocations. However, the exact mechanisms and pathways, which mediate genomic 
instability after c-MYC activation have remained elusive. 
 
1.2 Genomic instability: MIN and CIN 
It was shown that genetic instability is a common characteristic of most human 
cancers (Loeb, 2001; Rajagopalan et al., 2003). Genomic instability can be subdived 
into two classes. A small fraction of cancers displays defects in mismatch repair 
(MMR) system, which result in an elevated mutation rate at the nucleotide level. These 
mutations comprise base substitutions, deletions or insertions of few nucleotides. 
Often they occur in stretches of simple mono-, di- and trinucleotide repeats (e.g. 
(CA)n) as a consequence of DNA polymerase slippage errors during DNA replication. 
As a consequence widespread expansions and contractions of short, repetitive DNA 
sequences (called microsatellites) occur. Therefore, this type of instability has been 
named microsatellite instability (MIN). The majority of other cancers display abnormal 
chromosome number (aneuploidy) or/and structure, which is referred to as 
chromosomal instability (CIN).  
Defects in mutS and mutL genes were first found to cause MMR defficiency in 
bacteria and Saccharomyces cerevisiae. Germline mutations in the human homologs 
of these genes, MSH2 and MLH1, have been implicated in the hereditary 
nonpolyposis colon cancer (HNPCC) syndrome, and predispose to a variety of 
cancers. In mouse models homozygous deletion of the mismatch repair genes Msh2, 
Msh6, Mlh1, Pms2 or double mutant Msh3/Msh6 show a high incidence of tumor 
formation. Msh3 knockout mice display a low predisposition for tumor formation, 
furthermore Msh4-/-, Msh5-/- and Pms1-/- mice do not show elevated tumor formation 
  
3 
 
 
(Wei et al., 2002). Genetic screens in Saccharomyces cerevisiae for mutations which 
cause CIN identified several candidate genes. So called ‘’CIN genes’’ are involved in 
chromosome condensation, sister-chromatid cohesion, kinetochore structure and 
function, and microtubule formation as well as in cell cycle check-points. However, 
only a small number of human CIN genes has been identified until now (Rajagopalan 
et al., 2003). Germline mutations in several of them were shown to cause aneuploidy 
(hBub1, BubR1, Mad2, APC, BRCA1 and BRCA2). 
At the beginning of the last century chromosomal instability was already 
proposed as a potential cause of cancer by the german zoologist Theodor Boveri 
(Boveri, 1914; Hansemann, 1890). He observed that sea urchin embryos undergoing 
mitosis in the presence of multipolar spindles generated aneuploid progeny. 
Furthermore, he described that tumor cells frequently display aberrant chromosome 
numbers (aneuploidy). He proposed that aneuploidy itself may be the cause of cancer. 
This proposal is still a matter of debate. Opponents argue that CIN is irrelevant to 
tumor initiation (Hahn et al., 1999), but rather contributes to tumor progression 
(Zimonjic et al., 2001). Moreover, some authors proposed that aneuploidy is a side-
effect of transformation (Marx, 2002). The detailed molecular mechanism and 
determinants of aberrant chromosome segregation, which commonly occurs in cancer 
cells, are not clearly understood. However, it is obvious that the proper function of the 
spindle checkpoint is necessary for correct segregation of chromosomes and prevents 
aneuploidy. Any deregulation of the spindle checkpoint may therefore lead to CIN and 
as a consequence promote tumorigenesis.  
It was reported that tumor-associated viruses cause genomic instability in birds 
and rodents (Rous sarcoma virus (RSV))(Nichols et al., 1965). Also human 
papillomavirus E6 and E7 (HPV) (Duensing and Munger, 2002; Munger and Howley, 
2002; White et al., 1994; zur Hausen, 1991) and the viral protein v-src and its cellular 
homologs c-src cause CIN (Nanus et al., 1991). Additionally, the activation of 
endogenous proto-oncogenes like c-MYC (Alitalo and Schwab, 1986; Tsichlis, 1987), 
Ras (Denko et al., 1994; Kim et al., 2003) and Mos (Fukasawa and Vande Woude, 
1997) by diverse mechanisms results in structural and numerical chromosomal 
changes.     
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1.3 Mechanisms of c-MYC activation in cancer 
Over-expression of c-MYC has been found in up to 50% of all human cancers 
(Alitalo and Schwab, 1986; Pompetti et al., 1996). Elevated c-MYC expression 
correlates with clinically aggressive tumors, which have a worse prognosis than 
tumors without MYC over-expression (Gamberi et al., 1998). The activation of c-MYC 
occurs mainly through genomic and transcriptional alterations. One of the common 
genomic changes in hematopoietic malignancies as Burkitt’s lymphoma are 
translocations of the c-MYC gene, which is located on chromosome 8, to the 
immunoglobulin μ heavy chain or the λ and κ light chain enhancers located on 
chromosome 2, 14 or 22, respectively (Boxer and Dang, 2001; Dalla-Favera et al., 
1982; Popescu and Zimonjic, 2002). Rearrangements of c-MYC gene were also found 
in diffuse large cell lymphoma (DLCL), acute lymphocytic leukemia (AML), multiple 
myeloma (MM), and primary plasma cell leukemia (PCL) (Avet-Loiseau et al., 2001; 
Burmeister et al., 2005; Frost et al., 2004; Miranda Peralta et al., 1991; Nesbit et al., 
1999). Rare cases of T-cell leukemia, in which the c-MYC gene is translocated to T-
cell receptor, have also been reported (Harrison, 2000).  
The transcription of c-MYC is frequently activated by mutations in pathways 
upstream of c-MYC. E.g. mutations in the APC/β-catenin pathway lead to activation of 
c-MYC in colorectal cancer (He et al., 1998). c-MYC expression in malignant 
melanoma might also be deregulated via APC/β-catenin pathway, as β-catenin 
mutations were described in some cell lines (Rubinfeld et al., 1997). 
Another mechanism of c-MYC activation in solid tumors is gene amplification 
(Vita and Henriksson, 2006). In case of malignant melanoma, extra c-MYC copies 
were found in 61% of nodular melanomas, in 28% of superficially spreading 
melanomas, and in 30% of metastatic tumors (Treszl et al., 2004). Amplification of c-
Myc was detected in 40% of tumors with over-expression of c-MYC protein in ovarian 
cancer (Baker et al., 1990). In cervical cancer, the c-Myc gene is amplified in 29% of 
abnormal epithelia compared to 8% in control tissues (Abba et al., 2004). Up to 23% 
of lung carcinoma samples displayed amplifications (Gugger et al., 2002), which were 
also found in 10% of esophageal squamous cell carcinoma (SCC) patients treated by 
surgery and in 30% of patients subjected to multimodal treatment (Bitzer et al., 2003). 
All three transforming members of the Myc family have been shown to be amplified in 
small cell lung carcinoma (SCLC), with a frequency of 10% (MycN), 13% (L-Myc), and 
20% (c-Myc) (Gugger et al., 2002; Lui et al., 2001; Nesbit et al., 1999), whereas 30% 
  
5 
 
 
of all neuroblastoma (NBL) show specific amplification of MycN (Brodeur, 1994, 1995). 
In breast cancer c-MYC is amplified in 17.1%, whereas the HER2/neu was amplified in 
18.7% of analyzed cases (Berns et al., 1992). In prostate cancer, c-MYC amplification 
was detected at a frequency of 29% (Nupponen et al., 1998). Mutational inactivation of 
the Myc-antagonist Mxi-1 may be another mechanism of c-Myc activation in prostate 
carcinoma (Eagle et al., 1995; Prochownik et al., 1998). 
 
1.4 Potential mechanisms of c-Myc-induced genomic instability 
In solid tumors abnormal c-MYC expression correlates with genomic instability. 
In vivo and in vitro models of c-MYC overexpression revealed induction of karyotypic 
changes, including alterations in copy number and chromosomal rearrangements 
(Felsher and Bishop, 1999; Louis et al., 2005; Vafa et al., 2002) or locus specific 
instability involving amplification of certain genes (Kuschak et al., 1999; Mai, 1994; 
Mai et al., 1996b) (cyclin D2, ribonucleotide reductase R2, PALA, CAD, DHFR). After 
inactivation of MYC in conditional mice models most tumors undergo proliferative 
arrest, differentiation and apoptosis (Arvanitis and Felsher, 2006). However, some of 
tumors can become independent of MYC overexpression by acquiring additional 
genetic events such as chromosomal translocations (Felsher and Bishop, 1999; 
Karlsson et al., 2003; Louis et al., 2005; Vafa et al., 2002). These observations 
suggest that c-MYC functions as dominant mutator gene by promoting CIN. Identical 
translocations were present in multiple relapsed tumors arguing that these genomic 
events may contribute to the independence from c-MYC (Arvanitis and Felsher, 2006).  
 
1.4.1 Transition into S phase 
c-MYC activation is sufficient and necessary for induction of G1/S-
transition.(Eilers et al., 1989; Trumpp et al., 2001) In Drosophila ectopic expression of 
dMYC increases both cell mass and cell number (Johnston et al., 1999). Targeted 
disruption of the c-MYC gene in rat fibroblast resulted in a significant lengthening of 
the G1 and G2 phases, whereas the duration of S phase was not affected (Iritani and 
Eisenman, 1999; Johnston et al., 1999; Mateyak et al., 1997; Trumpp et al., 2001). c-
MYC induces transcription of several target genes involved in G1/S transition such as 
ODC, Cul1, CDK4, Cdc25A and Id2 (Bello-Fernandez et al., 1993; Berns et al., 1997; 
Galaktionov et al., 1996; Hermeking et al., 2000; Lasorella et al., 2000; Leone et al., 
1997; Muller et al., 1997; O'Hagan et al., 2000; Wagner et al., 1993). Furthermore, c-
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MYC activation leads to down-regulation of inhibitors of cyclin/CDK complexes. As a 
result, c-MYC leads to activation of cyclin/CDK complexes, phosporylation of pRB and 
release of active E2F/DP transcription factors (Blagosklonny and Pardee, 2002). 
 
Cul1 Cyclin E
Cul1
Cyclin E
p27 Cdk2
Cyclin E
Cyclin E
Cdk2
Cdk2
S phase entry
?
Rb
Rb
cdc25A
cdc25A
p27
degragation
c-MYC c-MYC c-MYC
a b c
Figure 1 c-MYC overcomes restriction point (adapted from (Wade and Wahl, 2006)). 
c-MYC transactivates expression of genes involved in regulation of CycinE/Cdk2 complex activity, 
which modulate Rb function, release E2Fs and facillitate progression through S-phase. (a) Up-
regulation of Cul1, a transcriptional target of c-MYC, leads to degradation of the Cyclin/Cdk2 inhibitor, 
p27. (b) c-MYC directly activates transcription of Cyclin E. (c) c-MYC dependent inducton of cdc25A 
phosphatase activates cdk2.  
 
Under such conditions inappropriate expression of cyclin E can lead to genomic 
instability (Spruck et al., 1999). Also, excessive CDK activity influences the fidelity of 
chromosome transmission, including the licensing of replication origins, which has 
been linked to instability (Hua et al., 1997; Walter et al., 1998) (Figure 1). In addition, 
studies in yeast suggested that precocious CDK activation may cause genomic 
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instability via delayed firing of replication origins, leading to breaks during mitosis of 
incompletely replicated chromosomes (Lengronne and Schwob, 2002). 
 
1.4.2 c-MYC overcomes DNA damage-induced G1/S arrest 
When genetic material is damaged, the activated checkpoints delay replication, 
allowing the DNA repair machinery to remove brakes. If the damage is too severe 
apoptosis is initiated to permanently remove damaged cells. After DNA damage 
activation of ATM and ATR are the initial steps (Bartek and Lukas, 2001b; Kastan and 
Bartek, 2004). For the DNA damage response at G1/S transition a two-wave 
checkpoint response has been suggested (Bartek and Lukas, 2001a; Falck et al., 
2001). The initial, transient response is an inhibition of Cdk2 within 20-30 minutes, 
which is restricted to several hours (Mailand et al., 2000; Rotman and Shiloh, 1999). 
This prompt cell cycle delay is independent of p53 and transcription, and is mediated 
via dephosphorylation of CDC2 by the phosphatase Cdc25A. This early response 
temporarily slows down cell cycle progression to provide more time for DNA repair. 
The second, delayed and significantly extended response is mediated by the 
transcription factor p53, which is activated by phosphorylation of ATM/ATR (on serine 
15) and the checkpoint kinases Chk2 and Chk1 (on serine 20). These modifications 
activate p53 either by decreasing p53 binding to its negative regulator, mdm2, or by 
increasing association with transcriptional co-activator p300/CBP (Lambert et al., 
1998; Unger et al., 1999). Activated p53 regulates transcription of a large number of 
genes leading to cell cycle arrest, apoptosis or increased DNA repair (Wahl and Carr, 
2001). Among them is the p21Waf1/Cip1, which encodes an inhibtor of cyclin dependent 
kinases (CDKs), which are essential for entry into S phase (Sherr and Roberts, 1999; 
Vogelstein et al., 2000). The process of p53 modification, accumulation, activation and 
finally transcriptional induction of the effectors requires several hours and may last for 
several days (Carr, 2000).  
G1 arrest caused by ionizing radiation-induced DNA damage is compromised 
by ectopic c-MYC overexpression (Sheen and Dickson, 2002). As a result cells 
perform DNA replication in the presence of DNA strand breaks which may ultimately 
lead to the generation of dicentric chromosomes and chromosomal instability. 
Abrogation of a p53-dependent arrest by constitutive c-MYC expression may results in 
apoptosis (Hermeking and Eick, 1994), which provides a safeguard mechanism to 
prevent the persistence genomic instability caused by oncogene activation. 
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Presumably, modulation of p21 protein levels by c-MYC can determine this apoptotic 
response. For example, DNA damage-induced accumulation of p21 protein can be 
specifically blocked by c-MYC/MIZ1 (Seoane et al., 2002). This reduction of p21 levels 
may redirect the response to DNA damage from arrest to apoptosis. However, in cells 
with defects in the apoptotic signalling pathway oncogenic, constitutive c-MYC 
expression allows cells to evade from DNA damage-induced arrest and apoptosis.     
 
DNA damage
ATM activation,
re-location
p53 activation
Apoptosis
Arrest
DNA repair
p53
Cyclin E
Cdk2
p21
Proapoptotic
genes
Apoptosis
p53
p21
Rb Rb
Arrest S phase entry
Strand breakage
Chromosomal
aberations
Apoptosis
c-MYC
Miz
c-MYC
b c
a
 
Figure 2. c-MYC activation abrogates the DNA damage response (adapted from 
(Wade and Wahl, 2006)). 
(a) The scheme describes the signaling downstream of DNA damage through ATM-dependent 
activation of p53 resulting in cell-type specific apoptosis or cell-cycle arrest with following DNA repair. 
(b) Heterodimerisation of c-MYC with Miz protein can specificaly block p21 induction from it promoter 
and result in apoptosis in some cell types. (c) Miz independent c-MYC-mediated p21 inhibition through 
sequestraton of it to the other cyclin-cdk complexes leads to cell-cycle entry.  
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1.4.3 c-MYC abrogates G2/M arrest 
The error-free transmission of genomic information to the next generation of 
cells requires complete, damage-free DNA replication and faithful mitotic segregation of 
chromosomes into two daughter cells. Checkpoint mechanisms in G2- and M-phase 
ensure the proper segregation of the duplicated chromosomes. Dysfunction of both G2 
and/or mitotic checkpoints may result in karyotypic abnormalities and/or 
endoreduplication (Bates et al., 1998; Niculescu et al., 1998; Stewart et al., 1999). 
Ectopic expression of c-MYC compromises a stable G2-arrest and causes 
aneuploidy and endoreduplication (Andreassen and Margolis, 1994; Khan and Wahl, 
1998; Kung et al., 1990; Lanni and Jacks, 1998; Li and Dang, 1999). c-MYC can 
compromise a G1-like arrest of cells undergoing mitotic slippage caused by drug-
induced microtubule perturbation (Li and Dang, 1999; Yin et al., 2001) or sequestration 
of E2F transcription factors (Li and Dang, 1999; Santoni-Rugiu et al., 2000) and leads 
to reduplication. p27 suppresses c-MYC-induced endoreduplication at low, but not at 
high levels of c-MYC expression (Deb-Basu et al., 2006). In the latter case no influence 
on c-MYC dependent chromosomal breaks or fusion formation was detected. A 
possible explanation for this observation is that p27 suppresses mitotic division and 
endoreduplication or the ability of c-MYC to cause accelerated entry into the S phase.  
The DNA damage generated by c-MYC over-expression is sufficient to activate 
the G2/M checkpoint (Felsher 2000) and arrest cells with a 4N DNA content (Felsher et 
al., 2000). Nevertheless, c-MYC activation is able to enforce G2 to S transition probably 
through the re-initiation of DNA synthesis or potential leakiness of the G2/M checkpoint. 
This bypass contributes to an increase in ploidy. An explanation for such mechanism 
could be the premature activation of cyclin/CDK complexes or other factors involved in 
replication origin licensing and initiation of S-phase by c-MYC.     
 
1.4.4 c-MYC modulates replication, DNA damage response and repair pathway    
c-MYC expression was also shown to influence processes which maintain the 
integrity of the genome such as DNA repair and the response to DNA damage. 
Perturbation or attenuation of these processes may contribute to genomic instability. 
Several gene expression studies revealed that c-MYC can upregulate genes 
involved in DNA replication including: MCM4, MCM6, MCM7, Cdt1, CDC6 and TOP1 
(Fernandez et al., 2003; O'Hagan et al., 2000; Schuhmacher et al., 1999; Watson et al., 
2002). In a proteomic approach c-MYC was recently shown to directly interact with 
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MCM7, RFC and others components of DNA replication machinery (Koch et al., 2007). 
Therefore, c-MYC activation presumably interferes with or modulates DNA replication, 
which in the case of constitutively active, oncogenic c-MYC expression may lead to 
induction of DNA damage and genomic instability (Labib and Diffley, 2001; Pourquier 
and Pommier, 2001).  
c-MYC overexpression also interferes with the repair of double strand breaks 
(DSBs) and results in an increase in chromosomal breaks and translocations (Karlsson 
et al., 2003). In this context it would be interesting to know whether c-MYC is able to 
inhibit repair directly via modulation of DNA damage response or repair genes or its 
function is more indirect.  
c-MYC dependent induction of DNA repair genes (Chiang et al., 2003; Grandori 
et al., 2003; Menssen and Hermeking, 2002) might have a dual effect on c-MYC-driven 
tumorigenesis. On one hand activation of repair genes might increase fidelity of DNA 
replication and facilitate resolution of breaks arising during replication and thus ensures 
replication fork progression. On the other hand, aberrant activation of repair enzymes 
may cause unscheduled repair of replication intermediates and increase the probability 
of chromosomal aberrations (Schar, 2001).  
 
1.4.5 c-MYC increases reactive oxygen species 
c-MYC couples mitogenic signalling to transcriptional induction of genes which 
promote growth and proliferation. Furthermore, c-MYC induces a numerous target 
genes involved in glycolytic, respiratory and biosynthetic pathways (Gomez-Roman et 
al., 2003; O'Connell et al., 2003; Shim et al., 1997). Rapid elevation of metabolism 
associated with transition from quiescence to S-phase could potentially lead to 
permanent accumulation of reactive oxygen species (ROS), which may cause 
modifications and breaks of genomic DNA. Several studies suggest that c-MYC 
induces ROS which generate DNA damage (Tanaka et al., 2002; Vafa et al., 2002). 
However, other authors suggest that c-MYC induces genomic instability through 
inappropriate cell cycle entry and progression (Felsher and Bishop, 1999). 
Interestingly, c-MYC also induces oxidative stress and DNA lesions in resting cells 
(Felsher and Bishop, 1999)(Mai et al., 1996a)(Vafa et al., 2002).  
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1.4.6 c-MYC induces telomere remodeling 
Telomere organisation and behaviour appear to be cell cycle-dependent 
(Chuang et al., 2004). During the G0/G1- and S-phases of normal cells telomeres are 
widely distributed throughout the nucleus, however in G2, they change positions and 
organize in telomeric discs and align in the center of the interphase nucleus (Mai and 
Garini, 2005). Tumor cells have distorted telomeric structures and display telomeric 
aggregate formation (Chuang et al., 2004). Interestingly, c-MYC activation induces 
telomeric aggregates in immortalized cells, which are accompanied by breakage-
bridge-fusion cycles and result in unbalanced chromosomal translocations (Louis et 
al., 2005). 
 
1.5 The spindle assembly checkpoint 
The mitotic checkpoint, also known as spindle assembly checkpoint (SAC) 
prevents chromosomal missegregation by inhibiting the irreversible transition through 
anaphase. Only when each chromatide has made proper attachments to microtubules 
connected to opposite spindle poles anaphase is initiated. This mechanisms ensures 
even and accurate chromosome separation onto two daughter cells and can therefore 
be envisioned as a tumour suppressive mechanism, which prevents the acquisition of 
oncogenic chromosomal missegregations. The connection between chromosomes 
and spindle microtubules occurs on so called kinetochores, attachment sites, which 
assemble from proteins and centromeric DNA during every mitosis. The outer surface 
of unattached kinetochores acts as a catalytic site which recruits mitotic checkpoint 
proteins (Bub1, BubR1, Bub3, Mad1, Mad2, MPS1 and CENP) and converts them to 
partially diffusible complexes that comprise a ‘’wait anaphase’’ signal, which inhibits 
the anaphase promoting complex/cyclosome (APC/C), preventing premature 
chromosome segregation until each kinetochore properly attaches to the mitotic 
spindle. The function of the APC/C E3 ubiquitin ligase, on which the mitotic checkpoint 
signaling converges, is ubiquitination of mitotic substrates whose subsequent 
proteasome-mediated destruction is necessary for the onset of anaphase (securin) 
and mitotic exit (cyclin B). Activated complexes of the inhibitors Bub3, BubR1 and 
Mad2 directly bind to CDC20, a specificity factor required for recognition of mitotic 
substrates by the APC/C. As soon as both kinetochores of a sister chromatide are 
attached to microtubule of the opposite spindle poles through microtubule motors 
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(CENP-E), tension is generated by this motor, which leads to silencing of checkpoint 
inhibitor at those kinetochores (Figure 3).   
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Figure 3. The mammalian mitotic checkpoint signaling. (adapted from (Kops et al., 
2005)) 
(a) Prophase-early prometaphase. After nuclear envelope breakdown pools of spindle checkpoint 
protiens occupy kinetochors of unattached chromosomes. CENP-E protein bound to the kinetochor and 
not attached to the spindle microtubules activates BubR1 kinase activity which further facilitates 
recruitment of MAD1-MAD2 heterodimers to kinetochores for transmiting a ‘’wait anaphase signal’’. 
Presense of other essential checkpoint components leads to recruitment and conformational activation 
of MAD2 through the MAD1-MAD2 heterodimer. These events, which occur on free kinetochors, 
generate a pool of activeted MAD2 and BubR1 molecules which in combination with BUB3 deplete 
CDC20 preventing activation by APC/C. Thereby, cyclin B1 and securin degradation is inhibited (b) As 
soon as all kinetochors attach to the microtubulie spindles from opposite poles the microtubule motor 
proteins stretch the sister chromatides via microtubules, which terminates the ‘’wait anaphase signal’’. 
(c) As the ’’wait anaphase signal’’ ceases the APC/C-mediated ubiquitinitation of cyclin B1 and securin 
triggers transition into anaphase. 
 
Interestingly, mitotic checkpoint proteins are present through interphase and 
participate in additional cellular processes besides chromosomal segregation. For 
instance, MAD1 and MAD2 bind to the nuclear envelope and pores (Campbell et al., 
2001; Iouk et al., 2002), MAD2 participates in the DNA replication checkpoint 
(Sugimoto et al., 2004). Bub3 is involved in transcriptional repression via interaction 
with histone deacetylases (Yoon et al., 2004). The BubR1 protein is implicated in 
variety of processes like premature aging (Baker et al., 2004), fertility (Baker et al., 
2004), megakaryopoesis (Wang et al., 2004a), response to DNA damage (Fang et al., 
2006) and apoptosis (Baek et al., 2005; Kim et al., 2005; Shin et al., 2003). Mitotic 
checkpoint proteins are also involved in promoting of gross chromosomal 
rearrangements in yeast (Myung et al., 2004). 
Dysfunction of the spindle checkpoint machinery leads to improper propagation 
of chromosomes through mitosis and causes aneuploidy and susceptibility to 
tumorigenesis. Several mouse models were described which characterized the 
function of a particular checkpoint genes, such as mitotic arrest deficient (MAD) MAD1 
(Iwanaga et al., 2007; Kienitz et al., 2005) and MAD2 (Dobles et al., 2000; Hernando 
et al., 2004; Michel et al., 2001; Sotillo et al., 2007), budding uninhibited by 
benzimidazoles (BUB) proteins Bub3 (Babu et al., 2003; Baker et al., 2006; Kalitsis et 
al., 2005) and BubR1 (Baker et al., 2006; Dai et al., 2004), and kinesin-like motor 
CENtromere-associated Protein-E CENP-E (Weaver et al., 2007). Complete loss of 
spindle checkpoint proteins is lethal for cells (Babu et al., 2003; Dobles et al., 2000; 
Wang et al., 2004a) and leads to massive chromosome missegragation and 
catastrophic cell death (Kops et al., 2004; Michel et al., 2004). MAD1 
haploinsufficiency or down-regulation both in human and mouse cells results in 
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elevated levels of aneuploidy. In mouse models MAD1+/- littermates show a 2-fold 
higher incidence of constitutive tumors in comparison to wild-type mice and develop 
neoplasia upon vincristine treatment (Iwanaga et al., 2007). In MAD2 haploinsufficient 
models cells display elevated rates of chromosome missegregation and mice develop 
spontaneous lung tumors after long latencies (Michel et al., 2001). Interestingly, 
overexpression of MAD2 in transgenic mice leads to much higher incidences of 
aneuploidy characterized as appearance of broken chromosomes, anaphase bridges 
and whole-chromosome gains and losses, and wide spectrum of tumors with relatively 
short latencies, high incidence and aggressiveness in comparison to haploinsufficient 
MAD2 mice (Sotillo et al., 2007; van Deursen, 2007). MAD2 overexpression was 
shown to cause aneuploidy in human cells (Hernando et al., 2004). High level of 
MAD2 was detected in a set of tumors such as lymphomas and neuroblastomas 
where c-MYC and MYCN are involved in tumorigenesis, respectively (Hernando et al., 
2004; Sotillo et al., 2007). This suggests that MAD2 activation is an oncogenic event 
in these models. Haplo-insufficiency of Bub3 leads to chromosome missegragation, 
but mice do not show any spontaneous tumorigenesis. They however, exhibit 
susceptibility to chemical induced lung tumors (Babu et al., 2003; Baker et al., 2006; 
Kalitsis et al., 2005). BubR1+/- mice display elevated levels of aneuploidy and rapidly 
developed tumors upon carcinogen treatment (Baker et al., 2006; Dai et al., 2004). 
BubR1+/-ApcMin/+ mutant mice develop colonic tumors 10 times more efficient then 
ApcMin/+ mice (Rao et al., 2005). This observation supports the idea that c-MYC 
activation, caused due to Apc inactivation, leads to increased tumorigenesis due to the 
compromised spindle checkpoint caused by BubR1 haploinsufficiency. Therefore, the 
spindle checkpoint may have a tumor suppressive function. The most recently 
reported mouse model showed that down-regulation of the centromere-associated 
motor protein CENP-E leads to an increased rate of chromosomal instability and 
elevated levels of spontaneous tumors in aged animals (Weaver et al., 2007). 
Unexpectedly, chromosomal instability caused by CENP-E reduction was shown to 
rather inhibit chemically or genetically induced tumorigenesis.  
Meanwhile, it has been shown that genetic instability caused by CIN or MIN is 
an inherent feature of most cancer cells which promotes carcinogenesis by increasing 
the rate of mutations in critical genes and thereby allows unrestrained growth and 
metastasis (Lengauer, 2005; Rajagopalan and Lengauer, 2004). As mutations in 
genes encoding components of the SAC occur at a low frequency (Cahill et al., 1999; 
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Hernando et al., 2001; Wang et al., 2004b), other cancer-specific alterations are 
suspected to contribute to CIN. 
 
1.6 RNA interference  
RNA interference was discovered almost a decade ago and became a very 
elegant and effective method for probing gene function, and thereby also revolutionized 
the genetic analysis in mammalian cellular systems (Hannon, 2002; Meister and 
Tuschl, 2004; Paddison and Hannon, 2002; Paddison et al., 2004; Silva et al., 2004) 
(Figure 4). RNAi allows the modulation of gene expression at more physiological 
conditions in comparison to ecopic gene expression systems, and has advantages 
when applied to functional genetics analyses: it allows to modulate gene expression 
with high efficiency, specifically turn off gene isoforms or allelic variants, or repress 
endogenous RNA in the presence of a mutant transcript of the same gene. 
Furthermore, various loss-of-function screens were made possible by RNA 
intereference. In the last years RNAi was also applied to gene therapeutic approaches, 
where it has great potential but faces problems as efficient delivery and tissue 
specificity (Aagaard and Rossi, 2007; Kim and Rossi, 2007; Li et al., 2006; Martin and 
Caplen, 2007). In cellular systems there are several ways to achieve RNAi: (1) direct 
delivery of dsRNA (double stranded RNA) or (2) transfection of siRNA (short interfering 
RNA) duplexes and (3) stable expression of shRNA/miRNAs (short hairpin/microRNAs) 
from plasmids. These approaches function through different pathways to cause down-
regulation of protein expression (Figure 4). For a number of applications expression 
vector based systems were advantageous and have been modified in several 
directions to reach effective gene silencing, simple and effective delivery into the cells 
and stable integration. The application of conditional regulation (doxycycline- or 
ecdysone-controlled units and Cre- or Flp-dependent recombination) allows the 
analysis of ‘’off’’ and ‘’on’’ states of gene expression and the functional analysis of 
essential genes (Wiznerowicz et al., 2006). The major problem of conditional systems 
is leakiness. Even a slight basal shRNA expression might cause a pronounced 
phenotype due to the catalytic nature of RNAi. Two types of promoters driving 
transcription by Pol-III or Pol-II systems are currently available (Bernards et al., 2006; 
Dickins et al., 2005; Root et al., 2006; Wadhwa et al., 2004). The U6 and H1 based 
Polymerase III promoters have the advantage of generating small-sized shRNA  
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Figure 4. A model of post-transcriptional gene silencing by RNAi. (adapted from 
(Filipowicz et al., 2005; Meister and Tuschl, 2004)). 
dsRNA can be delivered into the cells by different ways. (a) Processing of dsRNA by Dicer produces 21-
23 nucleotide dsRNA intermediates. RNA helicase Armitage and R2D2 unwind them and incorporate 
single-stranded RNA into the RISC complex, which mediates sequence-specific mRNA cleavage. 
Primary miRNA transcipts are processed by the Drosha enzyme in the nucleus and exported into the 
cytoplasm. (b) The miRNA hairpin is further processed by Dicer, unwound and incorporated into the 
miRNP/RISC complex. Such single-stranded RNAs bound to Ago proteins mediate translational 
repression of target mRNAs. The initiation of cleavage or translation repression mechanism is 
determined by the complementarity of the miRNA with the target sequence. 
 
transcripts, high activity in most cell types and robust level of knockdown. Pol-II 
promoters were also used to express either shRNA or miRNA cassettes and achieve 
higher levels of transcript expression compared to Pol-III systems. These promoters 
were integrated into retro- or lenti-viral vectors, which allow stable integration into the 
genome. Futhermore, expression vectors can contain a number of useful features: 
antibiotic selection markers, tracking fluorescent or receptor proteins, tet repressors 
and/or activators, cDNAs of interest and bar codes for rapid identification using micro-
arrays. The currently available bar code systems are based on expression of shRNA 
and shRNAmir cassettes (Fewell and Schmitt, 2006). shRNAmir transcripts processed 
by both Drosha and Dicer have higher target specificity and produce more RNAs for 
incorporation into RISC complexes for subsequent mRNA degradation than standard 
shRNAs. Recently developed libraries of both shRNA and shRNAmir expressing 
vectors allow to perform genome-wide screens for gene functions.  
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2. Aim of the study 
 
The present study had the following aims: 
 
1. To investigate whether c-MYC activation affects the progression through mitosis. 
 
2. To identify direct c-MYC target genes which may affect mitotic progression. 
 
3. To determine whether potential effects of c-MYC on mitosis result  
    in chromosomal instability 
 
4. To develop an episomal vector system for conditional expression of microRNAs. 
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3. Materials 
 
3.1 Chemicals 
Reagent Supplier 
Antifade solution Vector Laboratories, Ltd., Peterborough 
3-Amino-1,2,4-triazole Sigma-Aldrich GmbH, Deisenhofen 
Agarose PEQLAB Biotechnologie GmbH, Erlangen 
Ampicillin Roche Diagnostics GmbH, Mannheim 
Ammonium peroxodisulfate (APS) Bio-Rad Laboratories GmbH, Munich 
Acrylamide SERVA Electrophoresis GmbH, Heidelberg 
Bradford protein assay Bio-Rad Laboratories GmbH, Munich 
Bacto® agar Becton Dickinson GmbH, Heidelberg 
Bacto® tryptone Becton Dickinson GmbH, Heidelberg 
Bacto® yeast extract Becton Dickinson GmbH, Heidelberg 
β-Mercaptoethanol Merck KGaA, Darmstadt 
Bisacrylamide Carl Roth GmbH & Co, Karlsruhe 
Bovine serum albumin (BSA) New England Biolabs GmbH, Frankfurt 
Bromphenol blue  Sigma-Aldrich GmbH, Deisenhofen 
Caffein Sigma-Aldrich GmbH, Deisenhofen 
Complete mini protease inhibitor cocktail Roche Diagnostics GmbH, Mannheim 
Coomassie G250  SERVA Electrophoresis GmbH, Heidelberg 
Chloramphenicol Sigma-Aldrich GmbH, Deisenhofen 
Chloroquine diphosphate  Sigma-Aldrich GmbH, Deisenhofen 
Carbenecillin Sigma-Aldrich GmbH, Deisenhofen 
Deoxynucleotides triphosphate (dNTPs) ABgene Deutschland, Hamburg 
DABCO (1,4-Diazabicyclo[2,2,2]octane)  Sigma-Aldrich GmbH, Deisenhofen 
DAPI (2-(4-Amidinophenyl)-6-indolecarb Sigma-Aldrich GmbH, Deisenhofen 
Dithiothreitol (DTT)  Sigma-Aldrich GmbH, Deisenhofen 
DMSO Sigma-Aldrich GmbH, Deisenhofen 
Doxycycline hydrochloride  Sigma-Aldrich GmbH, Deisenhofen 
DL-p-chlorophenylalanine Sigma-Aldrich GmbH, Deisenhofen 
DMEM (Dulbecco's modified eagle 
medium) 
Invitrogen GmbH, Karlsruhe 
Demicolcine solution Sigma-Aldrich GmbH, Deisenhofen 
DNA/RNA oligonucleotides Metabion GmbH, Martinsried 
 MWG Biotech AG, Ebersberg 
Ethidium bromide  Carl Roth GmbH & Co, Karlsruhe 
Ethanolamine Sigma-Aldrich GmbH, Deisenhofen 
Ethanol Carl Roth GmbH & Co, Karlsruhe 
FuGENE®6 transfection reagent  Roche Diagnostics GmbH, Mannheim 
Ficoll® 400  Sigma-Aldrich GmbH, Deisenhofen 
Foetal bovine serum (FBS)  Perbio Science Deutschland GmbH, Bonn 
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Glycogen from mussels  Roche Diagnostics GmbH, Mannheim 
Geneticin® (G418)  Invitrogen GmbH, Karlsruhe 
Glucose Sigma-Aldrich GmbH, Deisenhofen 
4 hydroxytamoxifen (4-OHT) Sigma-Aldrich GmbH, Deisenhofen 
Hanks' balanced salt solution (HBSS)  Invitrogen GmbH, Karlsruhe 
Hygromycin B (HygB)  Invitrogen GmbH, Karlsruhe 
Herring sperm carrier DNA  Promega GmbH, Mannheim 
HighPerefect QIAGEN GmbH, Hilden 
Isopropanol Sigma-Aldrich GmbH, Deisenhofen 
Kanamycin Sigma-Aldrich GmbH, Deisenhofen 
Lipofectamine™ 2000  Invitrogen GmbH, Karlsruhe 
L-Glutamine (200 mM)  Invitrogen GmbH, Karlsruhe 
L-arabinose Sigma-Aldrich GmbH, Deisenhofen 
L-rhamnose Sigma-Aldrich GmbH, Deisenhofen 
McCoy's 5A medium  Invitrogen GmbH, Karlsruhe 
Methanol Carl Roth GmbH & Co, Karlsruhe 
Nocodazol Sigma-Aldrich GmbH, Deisenhofen 
Nonidet-P40 (NP40)  Sigma-Aldrich GmbH, Deisenhofen 
OptiMEM®I reduced-serum medium  Invitrogen GmbH, Karlsruhe 
Paraformaldehyde Merck KGaA, Darmstadt 
Phenol/chloroform/isoamylalcohol 
(25/24/1)  
Carl Roth GmbH & Co, Karlsruhe 
Phosphatase inhibitor cocktail 1  Sigma-Aldrich GmbH, Deisenhofen 
Protein A-sepharose®  Sigma-Aldrich GmbH, Deisenhofen 
Puromycin dihydrochloride  Sigma-Aldrich GmbH, Deisenhofen 
Penicillin-streptomycin Invitrogen GmbH, Karlsruhe 
PageRuler™ prestained protein ladder Fermentas GmbH, St. Leon-Rot 
Propidium Iodid ICN Biomedicals, CA 
Sodium dodecyl sulfate (SDS)  Carl Roth GmbH & Co, Karlsruhe 
Sodium orthovanadate  Sigma-Aldrich GmbH, Deisenhofen 
Skim milk powder  Fluka Chemie AG, Buchs (CH) 
Spectinomycin Sigma-Aldrich GmbH, Deisenhofen 
Triton X-100  Carl Roth GmbH & Co, Karlsruhe 
Tetracycline Sigma-Aldrich GmbH, Deisenhofen 
Tween® 20  Sigma-Aldrich GmbH, Deisenhofen 
YPD-agar / YPD-broth  Sigma-Aldrich GmbH, Deisenhofen 
Yeast nitrogen base without amino acids Fisher Scientific GmbH, Schwerte 
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3.2 Reagents 
 
Reagent Supplier 
Alkaline phosphatase, shrimp (1 U/µl)  Roche Diagnostics GmbH, Mannheim 
DNAse I, RNAse-free (10 U/µl)  Roche Diagnostics GmbH, Mannheim 
FIREPol® DNA polymerase (5 U/µl)  Solis BioDyne, Tartu (EE) 
Platinum® Taq DNA polymerase (5 U/µl) Invitrogen GmbH, Karlsruhe 
Restriction endonucleases (3-50 U/µl)  Fermentas GmbH, St. Leon-Rot 
 New England Biolabs GmbH, Frankfurt 
 Promega GmbH, Mannheim 
RNAse A Sigma-Aldrich GmbH, Deisenhofen 
T4 DNA ligase (400 U/µl) New England Biolabs GmbH, Frankfurt 
Trypsin-EDTA  Invitrogen GmbH, Karlsruhe 
Proteinase K Sigma-Aldrich GmbH, Deisenhofen 
 
3.3 Antibodies 
3.3.1 Primary antibodies 
Antibody Supplier 
Rabbit polyclonal anti-β-actin Sigma-Aldrich GmbH, Deisenhofen 
Mouse monoclonal anti-α-tubulin Sigma-Aldrich GmbH, Deisenhofen 
Mouse monoclonal anti-γ-tubulin Sigma-Aldrich GmbH, Deisenhofen 
Mouse monoclonal anti-Mad2 BD Biosciences Pharmingen 
Mouse monoclonal anti-γ-H2AX (Ser139) 
clone JBW301 
Upstate cell signaling solutions, CA 
Mouse monoclonal [8G1] anti-BubR1 
(ab4637) 
BIOZOL Diagnostica Vertrieb GmbH, Eching 
Rabbit polyclonal anti-c-Myc (sc-764) Santa Cruz Biotechnology, California 
Rabbit anti mouse IgG (M-7023) Sigma-Aldrich GmbH, Deisenhofen 
 
3.3.2 Secondary antibodies 
Antibody Supplier 
Goat anti-mouse IgG HRP-conjugate Promega GmbH, Mannheim 
Goat anti-rabbit IgGHRP-conjugate Sigma-Aldrich GmbH, Deisenhofen 
Goat anti-mouse IgG Cy3-conjugate Jackson ImmunoResearch Laboratories, Inc. 
Newmarket 
 
3.4 DNA constructs 
Plasmid Refernce/Supplier 
pRTS-1 Bornkamm et al., 2005 
pEMI Epanchintsev et al., 2006 
pShumi Epanchintsev et al., 2006 
TOPO-TA vector (pCR®4-TOPO) Invitrogen GmbH, Karlsruhe 
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LMP Dickins et al., 2005 
TMP Dickins et al., 2005 
pPRIME Stegmeier et al., 2005 
pSMc2 Open Biosystems 
pUC19 Universety of California 
pSuper Brummelkamp et al., 2002b 
pRetroSuper Brummelkamp et al., 2002a 
pMYC-eYFP-N1 Koch et al., 2007 
pLPCX - H2B-GFP Gift from Stephen Taylor 
pcDNA3.1-H2B-YFP Gift from Dmitri Lodygin 
pMK10tTA Gift from Bert Vogelstein 
 
3.5 Bacteria strains 
Bacteria strain Genotype Reference/Supplier
DH10βF’FOT sbcC  mcrAΔ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 deoR recA1 end A1 araΔ139 
Δ(ara,leu)7697 galU galK λ- rpsL nupG 
tonA umuC::pir116-frt F’(lac+ pro+ 
ΔoriT::Tc) sbcC::Frt 
Li et al. 2005 
 
BW28705I/pML300  LacIq rrnB3 ΔlacZ4787 hsdR514 
Δ(araBAD)567 Δ(rhaBAD)568 galU95 
ΔendA9::FRT ΔrecA635::FRT 
umuC::ParaBAD-I-SceI-FRT + 
pML300(PrhaB-γβexo Ts(ori) 
Spectinomycin resistant) 
Li et al. 2005 
E. coli XL1-Blue  endA1 gyrA96 hsdR17 lac- recA1 relA1 
supE44 thi-1 [F' lacIq Z ΔM15, proAB, Tn 
10, TetR] 
Stratagene GmbH, 
Heidelbeg 
 
3.6 Disposable kits 
Product Supplier 
TOPO-TA cloning kit for sequencing  Invitrogen GmbH, Karlsruhe 
BigDye® terminator v3.1 sequencing mix Applera Deutschland GmbH, Darmstadt 
FastStart-DNA Master SYBR Green 1 kit Roche Diagnostics GmbH, Mannheim 
RNAgent RNA isolation kit  Promega GmbH, Mannheim 
Ribomax T7 in vitro transcription kit  Promega GmbH, Mannheim 
SuperScript™ III first strand cDNA 
synthesis kit  
Invitrogen GmbH, Karlsruhe 
QIAGEN Plasmid Maxi Kit  QIAGEN GmbH, Hilden 
QIAprep Spin Miniprep Kit  QIAGEN GmbH, Hilden 
QIAquick Gel Extraction Kit  QIAGEN GmbH, Hilden 
QIAquick PCR Purification Kit  QIAGEN GmbH, Hilden 
Nucleotide removal kit  QIAGEN GmbH, Hilden 
3MM Whatman® filter paper  Whatman GmbH, Dassel 
Immobilon-P PVDF Transfer Membrane  Millipore GmbH, Schwalbach 
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Pierce ECL Western blotting substrate  Pierce Biotechnology Inc., Rockford 
Western Lightning® Western Blot 
Chemiluminescence Reagent Plus 
PerkinElmer GmbH, Cologne 
0.45 µm Millex-HV filter units  Millipore GmbH, Schwalbach 
CELLocate gridded cover slips  Eppendorf, Hamburg 
Costar® Spin-X tubes  Corning GmbH, Kaiserslautern 
Lab-Tek® II Chamber Slide™ System  Nunc GmbH & Co. KG, Wiesbaden 
Tissue culture plastic ware  Corning GmbH, Kaiserslautern 
 Greiner bio-one, Frickenhausen 
 Nunc GmbH & Co. KG, Wiesbaden 
Dual-Luciferase® Reporter Assay 
System  
Promega GmbH, Mannheim 
 
3.7 Laboratory equipment 
Reagent Supplier 
Axiovert 25 microscope  Carl Zeiss GmbH, Oberkochen 
Axiovert 200M fluorescence microscope Carl Zeiss GmbH, Oberkochen 
Microscope Temperature Control System Life Imaging Services, Reihnach 
Ludin chamber  Life Imaging Services, Reihnach 
CoolSNAP™-HQ CCD camera  Photometrics, Tucson (USA) 
DXC-390P 3CCD camera Sony Electronics Inc., Tokyo (JP) 
HyperHAD CCD camera  Sony Electronics Inc., Tokyo (JP) 
KODAK Image Station 440CF  Eastman Kodak Company, Rochester (USA) 
KODAK Molecular Imaging Software  Eastman Kodak Company, Rochester (USA) 
MetaMorph® software  Universal Imaging, Downingtown (USA) 
GeneAmp® PCR System 9700  Applied Biosystems, Foster City (USA) 
LightCycler™ real-time PCR system  Roche Diagnostics GmbH, Mannheim 
Mini-PROTEAN® electrophoresis system Bio-Rad Laboratories GmbH, Munich 
Mini Trans-Blot® cell system  Bio-Rad Laboratories GmbH, Munich 
BioPhotometer  Eppendorf, Hamburg 
Neubauer counting chamber Carl Roth GmbH & Co, Karlsruhe 
Z1™ series Coulter counter®  Coulter electronics, Beds (UK) 
Phosphoimager BAS-2500 Fuji, Tokyo 
FACScan unit  BD Biosciences, Mountain View (USA) 
Tissue culture Lamin Air®  Heraeus Sepatech GmbH, Osterode 
Incubator for cell culture  Heraeus Sepatech GmbH, Osterode 
Sonicator Bandelin Sonopuls HD 70 w.    
MS73 Sonotrode (3 mm)) 
Bandelin Electronic GmbH & Co. KG, Berlin 
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4. Methods 
 
4.1 Bacterial cell culture 
4.1.1 Propagation of bacteria strains 
E. coli XL1-Blue bacteria strain was used for all conventional cloning procedures 
and grown at 37ºC. DH10βF'FOT sbcC and BW28705I/pML300 were used as a donor 
and recipient strains for mating experiments and grown at 37 and 30ºC. Laria-Bertani 
broth was used as complex medium for cloning and for growth of donor and recipient 
plasmids. To maintain plasmids, were added antibiotics as follows: ampicilin (100 
μg/ml), kanamycin (50 μg/ml), chloramphenicol (30 μg/ml), tetracycline (25 μg/ml) and 
spectinomycin (50 μg/ml). To reduce the background on plates after recombination 
carbenecillin (100 μg/ml) as a stronger antibiotic was used instead of ampicillin. IPTG 
(0.4 mM), L-arabinose (0.2% w/v) and L-rhamnose (0.2% w/v) were used to induce the 
Plac, ParaBAD and PrheB promoters, respectively. For conventional cloning transformed E. 
coli XL1-Blue was plated on LB-agar plates. Chloramphenicol agar plates (0.5% w/v 
yeast extract, 1% w/v NaCl, 0.4% w/v glycerol, 2% w/v agar, 10 mM DL-p-Cl-Phe and 
0.2% w/v arabinose) and the appropriate amounts of antibiotics for the counterselective 
marker PheS Gly294 were used in the final selection step. 
Competent bacteria of all used strains were generated by resuspension of lag-
proliferating bacteria in TSS-buffer and further freezing in nitrogen. 
 
4.1.2 Mating-assisted genetically integrated cloning (MAGIC) 
Ligation-free gene transfer using the MAGIC system was done essentially as 
described (Li and Elledge, 2005). In brief, the donor bacterial strain (DH10βF’DOT 
sbcC, PIR1 positive) was transformed with a p53-specific pSM2c vector and grown on 
kanamycin containing LB plates at 37ºC. The recipient strain (BW287051/pML300) was 
transformed with pEMI-recipient and grown in the presence of ampecillin, 
spectinomycin and glucose on LB plates at 30ºC. Donor and recipient colonies were 
used to inoculate overnight liquid cultures. The recipient strain was washed twice with 
LB. Both donor and recipient bacteria were diluted 1:50 with LB/0.2% (w/v) L-rhamnose 
and grown at 30ºC until an OD600 of 0.15-0.25. The bacteria were mixed for conjugation 
in the presence of 0.2% (w/v) L-arabinose and incubated at 37ºC for 2 h without and for 
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2 h with agitation. Recombinant bacteria were plated on a chloramphenicol agar plates 
and incubated at 42ºC overnight. Recombination events were detected by colony PCR 
using the primers (CmR-frw: 5’-CCGTTTGTGATGGCTTCCATGTC-3’ (corresponding 
to the chloramphenicol resistance) and pEMI-rev 5’-AATCAAGGGTCCCCAAACTC-3’ 
(matching to pEMI). 
 
4.2  Generation of plasmids 
4.2.1 pSHUMI/pEMI vector construction 
For generation of the shuttle vector pSHUMI the oligos pUC19linker-fw 5’-
AATTGGGCCTCACTGGCCACCGGAGATCTGTCGACGGACGCGTACCGGTG-3’ and 
pUC19linker-rv 5’-
TCGACACCGGTACGCGTCCGTCGACAGATCTCCGGTGGCCAGTGAGGCCC-3’  
were annealed and inserted into the EcoR I/Xho I sites of pUC19 resulting in pUC19m. 
A Bgl II/Age I fragment containing miR30 sequences from the LMP plasmid(Dickins et 
al., 2005) was inserted into the Bgl II/Age I sites of pUC19m. The resulting pSHUMI 
plasmid can be used to sub-clone short hairpin sequences using the Xho I and EcoR I 
restriction sites. 
For generation of the pEMI vector, regions containing 5’miR30 and homology 
region 2 (HR2) were amplified from pSM2c(Silva et al., 2005) using the primers 
5’miR30-frw 5’-CGAGATCTTGTTTGAATGAGGCTTCAGTAC-3’ and 5’miR30-rev 5’- 
GCACCGGTGCGGCCGCCTCGAGCCTTCTGTTGGGTTAACC-3’ and HR2-frw 5’-
CGCTCGAGATCCATGGCATATGGGATCCAAGGCAGTTATTGGTGCCCTTAAAC-3’ 
HR2-rev 5’-GCACCGGTTCAGATCCTCTTCGGAGATCAG -3’ and inserted into the 
pTOPO vector (Invitrogen). The 5’miR30 part was subcloned into pSHUMI using Bgl 
II/Age I restriction sites and the HR2 region was introduced using Xho I/Age I restriction 
sites. The PheS expressing cassette was released from pBSPheS(Li and Elledge, 
2005) using Nco I/Bgl II and ligated between the 5’miR30 and HR2 sequences into the 
Nco I/BamH I sites. From the resulting vector a fragment containing the 
5’miR30/PheS/HR2 region was released by Sfi I and inserted into the Sfi I sites of 
pRTS-1 resulting in pEMI (plasmid for episomal microRNAs). 
 
4.2.2 Restriction mediated microRNA transfer 
A p53-specific hairpin was released from pSM2c (Oligo ID: v2HS_93615, current 
accession: NM_000546)(Silva et al., 2005) using Xho I / EcoR I and inserted into 
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pSHUMI. MAD2-specific microRNA were generated in 2-step PCR: the primers fw 5’-
tgctgttgacagtgagcgCTGGGAAGAGTCGGGACCACAGtagtgaagccacagatg-3’ and rv 5’-
tccgaggcagtaggcaATGGGAAGAGTCGGGACCACAGtacatctgtggcttcac-3’ were 
annealed, extended by PCR and amplified using universal miR30XhoI/EcoRI primers 
(miR30Xho I Fw: 5’-CAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG-3’, 
miR30EcoR I Rv: 5’-CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA-3’. The 
resulting fragment was cut with Xho I and EcoR I and inserted into pSHUMI. The Sfi I 
fragments from pSHUMI containing the microRNA cassettes were inserted into pRTS-1 
(Bornkamm et al., 2005).  
 
4.2.3 Subcloning shRNA constructs into pRetroSuper 
Synthetic sense and antisense oligonucleotides specifically targeting the DP1 
(target sequence: ATGGCAAAAGATGCCGGTC), MAD2 (n1-
CTGGGAAGAGTCGGGACCA, n2- TACGGACTCACCTTGCTTG) or BubR1 (n1-
AGATCCTGGCTAACTGTTC, n2- AAGGGTTCAGAGCCATCAG) mRNA and a non-
silencing control (CTCGCTTGGGCGAGAGTAA) oligonucleotides were annealed, 
subjected to one PCR cycle, restricted and ligated into the pSUPER vector backbone. 
The hairpin-containing cassette was excised with EcoR I and Xho I, and subcloned 
into pRetro-SUPER (Brummelkamp et al., 2002). The insert was confirmed by 
sequencing.   
 
4.3 Cell culture and treatment 
The human colorectal cancer cell lines HCT116 and DLD-1 were maintained in 
McCoy’s 5A supplemented with 10% fetal bovine serum, U2Os and MCF-7/PJMMR1 
in DMEM with 10% FBS, LS174-T in RPMI with 5% FBS and the 293T-derived 
packaging cell line Phoenix-A in DMEM supplemented with 5% FBS. RAT1A 
fibroblasts (TGR-1 and HO15.19) and P493-6 B-cells were maintained as described 
previously (Hermeking et al., 2000). All cell lines were cultivated in presence of 100 
units/ml penicillin and 0.1 mg/ml streptomycin. Etoposide was resolved in DMSO 
(40 mg/ml) and used at a final concentration of 20 µg/ml. Poly I:C (Sigma) was 
resolved in water (10 mg/ml) and used at a final concentration of 10 µg/ml.  
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4.4 Generation of cell lines 
DLD-1 cells stably expressing a tetracycline regulated transactivator (DLD-1-
tTA) were a kind gift from Bert Vogelstein(Yu et al., 1999). DLD-1-tTA cells were 
transfected with pBI-c-MYC-HA and pTK-Hyg and selected in hygromycin B (250 
µg/ml) and G418 (500 µg/ml). After limiting dilution the clone DLD-1-tTA-MYC was 
characterized by Western blot analysis and indirect immunofluorescence 
(supplemental Figure 4). DLD-1-tTA-MYC cells were transfected with pcDNA3.1-H2B-
YFP and cultured in the presence of G418 (1 mg/ml) for two weeks, FACS-sorted for 
YFP expression and subjected to limiting dilution to generate single cell clones 
positive for H2B-YFP expression in the presence of 500 ng/ml DOX. The generation of 
MCF-7 cell lines conditionally expressing c-MYC (PJMMR1) under control of a tet-on 
system will be described elsewhere (Jung and Hermeking, in preparation). For virus 
production Phoenix-A packaging cells were transfected either with pRetro-SUPER-
shcontrol, pRetro-SUPER-shMAD2 (n1 or n2) or pRetro-SUPER-shBubR1 (n1 or n2) 
using calcium phosphate precipitation. Twenty-four hours after transfection, retrovirus 
containing supernatants were harvested, passed through 0.45 µm filters and used to 
infect DLD-1-H2B-YFP or PJMMR1 cells in the presence of polybrene (8 µg/ml) four 
times in four hour intervals. Twenty-four hours after infection the cells were split 1:10 
and selected for 10 days in the presence of 1-2 µg/ml puromycin. To visualize 
chromatin the resulting pools of resistant PJMMR1 cells were infected with a pLPCX 
retroviral vector expressing a H2B-GFP fusion protein.  
U2OS osteosarcoma cells were transfected by lipofection with pEMI-plasmids 
using FuGene reagents according to the manufacturer. After 48 hours cells were 
selected in media containing 150 µg/ml hygromycin for 7 days. Homogenicity of the 
selected cell pools was tested by addition of 100 ng/ml doxycycline for 24 hours and 
mRFP-fluorescence detection. 
 
4.5 Western blot analysis 
Cells were lysed for 15 minutes in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 
mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, 0.25% Na-deoxycholate, 1 mM PMSF, 
1 mM Na3VO4, protease inhibitor mixture (Complete Mini, Roche)). After sonication 
lysates were centrifuged for 20 minutes and 30-80 µg of protein were separated by gel 
electrophoresis using 9% or 12% TRIS-glycine gels. The proteins were transferred 
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onto PVDF membranes. After drying and brief incubation in methanol, the membranes 
were blocked with 10% skim milk/TBS-T (0.1% Tween-20) for 1-2 hours. The primary 
antibody was incubated in TBS-T. The membranes were washed and after using the 
respective HRP-conjugated secondary antibodies and washing with TBS, signals were 
obtained with enhanced chemiluminescence reagent, and recorded with a 440CF 
Kodak imaging system. Primary antibodies specific for c-MYC, MAD2, BubR1, p-53, 
p21, α-tubulin and β-actin were used. 
 
4.6 DNA content analysis by FACS 
5*10^4 U2OS or MCF7 cells were plated into T25 cell culture flasks. Floating 
cells and trypsinized cells were collected by centrifugation at 1.700 rpm for 7 minutes, 
cells were fixed with ice cold 70% ethanol and stored over night on ice. After washing 
with PBS, 1 ml FACS solution (PBS, 0.1% Triton X100, 60 µg/ml propidium iodide (PI), 
0.5 mg/ml DNase free RNase) was added per sample and incubated at room 
temperature for 30 min. DNA content was determined by propidium iodide staining. 
 
4.7 Indirect immunofluorescence 
Cells were fixed in 4% paraformaldehyde/PBS for 8 min, permeabilized in 0.2% 
Triton X-100 and blocked in 100% FBS. For detection of epitopes the following 
primary antibodies were used: anti-HA and α- or γ-tubulin. Images were acquired 
using 100x and 63x oil-immersion objectives and the MetaMorph software package. 
 
4.8 Micronucleus assessment 
Cells were washed with PBS and fixed in 4% formaldehyde/PBS at room 
temperature for 10 minutes. After washing with PBS, cells were incubated for 1 h at 
37oC in PBS with 1 µg/ml 4`6-diamidino-2-phenylindole (DAPI) and then embedded in 
antifade solution supplemented with 5 µg/ml DAPI. Micronuclei were microscopically 
determined as rounded chromatin fragments located adjacent to nuclei, with a 
diameter not exceeding one third of the diameter of the neighbouring nucleus. 
Microscopic analysis was performed with a 630x magnification. 
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4.9 Quantitative real-time PCR 
qPCR was performed using the LightCycler instrument and the FastStart DNA 
Master SYBR Green 1 kit (Roche Applied Science) as described previously (Menssen 
and Hermeking, 2002). Primer pairs where in use:  
 
Primer name qPCR primer 
DKC frw CGGCTGGTTATGAAAGAC 
DKC rev TGGTCGCAGGTAGAGATG 
MAD2 frw CCTGGAAAGATGGCAGTTTG 
MAD2 rev GTAAATGAACGAAGGCGGACT 
BubR1 fwr CTCTGGCTTCTCTGGTTCTTCT 
BubR1 rw CAACTTAGGCATTGGTCTGTCTT 
PHB frw CAGGTGGCTCAGCAGGAAGC 
PHB rev TGAAGTGATTTTACCTTTATTTCC 
β-actin frw TGACATTAAGGAGAAGCTGTGCTAC 
β-actin rev GAGTTGAAGGTAGTTTCGTGGATG 
DP-1 fwr ATGGCAAAAGATGCCGGTC 
DP-1 rev GTCGTCCTCGTCATTCTCGTT 
IFIT1-frw GCCATTTTCTTTGCTTCCCCTA 
IFIT1-rev TGCCCTTTTGTAGCCTCCTTG 
Mad2-specific-microRNA-frw GATGTACTGTGGTCCCGACTCT 
Mad2-specific-microRNA-rev TCAAAGAGATAGCAAGGTATTCAGT 
    
Primer name ChIP qPCR primer 
16q22/6000+frw CTACTCACTTATCCATCCAGGCTAC 
16q22/6000+ rev ATTTCACACACTCAGACATCACAG 
CAD PCR-I frw CCGCAGTCTCTGCTGCTG 
CAD PCR-I rev ATACGGAAAACGGGAAGGAC 
CAD PCR-A frw (control) TGGGTTTGGTAGGGGACATA 
CAD PCR-A rev (control) CTGGGCTCTGCTGGCTTA 
MAD2 ebC1 frw GACATCCTCTAGCCTCATAATCTG 
MAD2 ebA rev CAGCTATAAATGACTGAACACAC 
MAD2 I4 frw GCTGGCATCACTATTCTTGTG 
MAD2 I4 rev AGGTCATTTGGCTTGGTCTC 
BubR1 fwr GACACGGCCTGGTAGGTAAT 
BubR1 rev GCAGCCTTCTTCGCTTTG 
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4.10 Chromatin immunoprecipitation 
Chromatin immunoprecipitations (ChIP) were performed as described 
previously (Frank et al., 2001). PJMMR1 cells at <70% confluence were fixed in 1% 
formaldehyde. Chromatin was sheared to an average size of 500 bp by sonication (4x 
20sec on ice with 90sec intervals) at continuous maximum power setting. After pre-
clearing with pre-blocked protein A beads for 1 hour, lysates were rotated at 4°C for 
18 hours with a polyclonal antibody specific for c-MYC or rabbit anti mouse IgG. 
Washing and reversal of cross-linking was performed as described previously(Frank et 
al., 2001). Purified DNA was first analyzed by amplification of a genomic fragment 
from chromosome 16q22 that did not display any E-boxes up to 3 kb up- and 
downstream. This amplification product was used to control for equal DNA input into 
the PCR reactions. For the analysis of c-MYC binding to the MAD2 locus equal 
amounts of DNA were analyzed by PCR with a primer pair flanking the two E-boxes in 
the first intron of the human MAD2 gene. A second primer pair spanning the exon 4 
intron 4 boundaries was used to control for specificity of localized E-box binding. For 
analysis of BubR1 a primer pair flanking an E-box in the first intron of the BubR1 
genomic region was used. All PCR reactions were analyzed in the exponential phase. 
Enrichment of DNA-fragments bound by c-MYC was documented by gel-
electrophoresis and ethidium bromide staining. For oligonucleotide sequences see 
qPCR ChIP primer list in qPCR section. 
 
4.11 Time-lapse microscopy 
H2B-YFP/GFP pools were seeded in a 6 well plate and cultured for 36 hours 
before time lapse imaging. DOX concentrations were 100 ng/ml and 1 g/ml for DLD-
1 tTA Myc and PJMMR1 cells, respectively. Six hours before recording the cells were 
placed on inverted Axiovert 200M microscope surrounded by a chamber which 
provided a constant temperature of 37oC and a humidified atmosphere of 5% CO2. 
Images were recorded with a CCD camera and processed with the software 
MetaMorph. Digital pictures of phase contrast (100 ms) and YFP/GFP fluorescence 
(20-100 ms) were taken from four different positions of two separate wells for each 
state (with or without DOX) every 5 minutes over a period of 18 hours. Between the 
exposures cells were not exposed to halogen or UV light as it was blocked by a non-
transparent position in a motorized condenser. Allocation of individual frames to a 
particular stage of mitosis was done according to following criteria. In prophase, the 
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cell shape begins to change to rounded morphology and the chromatin condenses to 
the level of grain-like structure throughout nucleus and the nucleus itself slightly 
changes its shape before nuclear envelope breakdown. The following breakage of 
nuclear envelop determines beginning of pro-metaphase. After nuclear envelope 
completely dissolves, further condensation of chromatin is continued until distinct 
chromosomes are formed and organized in a plate. The metaphase was defined as a 
short stage, during which chromosomes clearly align in metaphase plate without any 
appearance of lagging chromosomes. The anaphase was defined as a stage when 
separation of sister chromatides to the opposite poles takes place. The duration of 
telophase was determined as time period between complete separation of 
chromatides and complete decondensation of chromatin in one of the daughter cells. 
Since sequential frames were taken in 5 minutes interval, minor changes in duration of 
specific stages were not detected.     
    
4.12 Tissue samples and immunohistochemistry 
15 consecutive cases of sporadic colorectal carcinomas were retrieved from the 
archives of the Institute of Pathology. All carcinomas were WHO grade 2 or 3. None of 
the patients had undergone cancer therapy before surgical resection of the lesions. 
For immunohistochemistry we used biopsies from diagnostic colonoscopies to ensure 
that the tumor tissue had been immediately fixed in neutral 4% buffered formalin. The 
primary antibodies applied were a c-MYC-specific (N-term) rabbit monoclonal 
(Epitomics) and a MAD2-specific mouse monoclonal (BD Transduction). Sections 
were deparaffinized and pretreated by microwave (750 W, 2 × 15 min) in TUF target 
unmasking fluid (Dako) for c-MYC and target retrieval solution (Dako) for MAD2. 
Sections were covered with hydrogen peroxide at a final concentration of 7.5% for 10 
minutes and then blocked with serum (Vector, Vectastain ABC Kit Elite Universal). 
Primary antibody (c-MYC) was used at a dilution 1:20, MAD2 1:50 for 60 min. For 
detection a biotinylated secondary antibody was used (Vector, Vectastain ABC Kit 
Elite Universal). Sections were treated with chromogen (AEC Zymed) for 10 min and 
counterstained with hematoxylin Gill’s Formula (Vector). 
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4.13 Statistical analysis 
The Chi square test was used to determine statistical significance in 
comparisons of micronucleus frequencies. In the figures, if not indicated explicitly 
columns and bars show the mean and standard deviation, respectively. 
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5. Results 
 
5.1 c-MYC directly transactivates MAD2 and BubR1 genes 
MAD2 mRNA induction was identified in a micro-array analysis of genes 
expression altered upon adenoviral expression of c-MYC in primary human endothelial 
cells (Menssen et al., data not shown). These data were independently confirmed by 
quantitative, real-time PCR (qPCR) in two additional cell types: MAD2 mRNA was 
induced after activation of a tetracycline regulated c-MYC allele in the B-cell line P493-
6 (Menssen et al., data not shown) and in the breast cancer cell line MCF-7/PJMMR1 
(Figure 5 a).  
The induction of MAD2 by c-MYC motivated us to analyze whether other 
important components of the SAC are also induced by c-MYC. CDC20, BubR1, Bub1, 
Bub3, MPS1, MAD1, Cenp-E and Cenp-J were inspected for the presence of E-boxes 
in close proximity to transcriptional start site (+/- 2 kbp) and for a significant induction 
of mRNA in the micro-array data sets of genes induced by c-MYC. Futhermore, a 
micro-array screen in PJMMR1 cells harboring an inducible c-MYC allele, revealed 
that BubR1 mRNA was up-regulated upon c-MYC activation (Jung et al., unpublished 
results). The induction of BubR1 mRNA was confirmed by qPCR analysis (Figure 5b). 
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Figure 5 Quantative real-time PCR (qPCR) analysis of MAD2 and BubR1 mRNA 
expression in PJMMR1 cell lines  
 
(a) qPCR determination of mRNA expression after activation of a conditional c-MYC allele in MCF-7 
cells. PJMMR1 cells were treated with 1 µg/ml of the anti-estrogen ICI 182,780 for 72 hours. For 
induction of ectopic c-MYC, 1 µg/ml doxycycline was added for 12 h. Fold induction of the indicated 
mRNAs was determined by qPCR relative to β-actin in biological triplicates. The induction of the known 
c-MYC target Prohibitin served as positive controls. (the analysis was performed by Dr. Antje Menssen, 
MPI of Biochemistry). (b) qPCR determination of BubR1 mRNA expression after c-MYC activation in 
MCF7 cells. PJMMR1 cells were treated as described in (a) and then stimulated with 1 μg/ml of DOX 
for the indicated periods. Relative induction of BubR1 mRNA in comparison to β-actin mRNA was 
determined by qPCR in three independent experiments. 
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Figure 6 Increase of MAD2 and BubR1 proteins level upon activation of c-MYC 
expression 
 
(a) Cells were treated as described in Figure 1 b. Lysates obtained at the indicated time points were 
subjected to Western blot analysis to detect the indicated epitopes. β-actin served as loading control. 
(the analysis was performed by Dr. Antje Menssen, MPI of Biochemestry). (b) Western blot analysis of 
BubR1 protein expression after c-MYC activation in PJMMR1 cells. Cells were treated as in (Figure 5 b) 
and lysates were subjected to Western blot analysis. The membrane was probed for c-MYC and BubR1 
epitopes, β-actin served as loading control. 
 
The increase in MAD2 and BubR1 mRNAs was accompanied by an increase in MAD2 
and BubR1 protein in PJMMR1 after activation of c-MYC (Figure 6, a and b). The 
induction of these genes was also found in the colorectal cancer cell line DLD-1 
harboring a conditional c-MYC allele (Figure 11, a and b). Taken together these 
results suggested that c-MYC may directly regulate MAD2 and BubR1 expression.  
To prove that c-MYC can directly activate MAD2 expression, and exclude 
indirect transcriptional activation through the E2F transcription machinery (Hernando 
et al., 2004; Sears et al., 1997), c-MYC dependent MAD2 induction was studied in the 
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presence of inhibition of DP-1, which heterodimerizes with E2F and is necessary for 
DNA binding. The down-regulation of DP-1 was achieved by retroviral infection of 
shRNA expressing construct directed against DP1 and confirmed on mRNA level by 
qPCR (Figure 7a).  
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Figure 7 c-MYC induces MAD2 protein expression in the presence of DP1 knockdown 
(a) Analysis of DP1 mRNA expression in PJMMR1 cell lines. Relative fold of mRNA reduction was 
measured by qPCR analysis in PJMMR1 cells infected either with non-silenced retroviral construct or 
expressing a shRNA directed against the DP1 coding region. (b) Western blot analysis of MAD2 
protein induction upon activation of a conditional c-MYC allele in PJMMR1 cells. Cells were treated as 
describe in Figure 6b. Protein lysates were harvested at the indicated time points. The membrane was 
probed against the indicated epitopes, with β-actin serving as a loading control.  
 
 
   The efficiency of the E2F pathway inactivation was confirmed by RT-PCR analysis 
for the genes controlled either by E2F1, c-MYC or not involved in transcriptional 
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regulation by them (data not shown). In the presence of a DP1 knockdown c-MYC 
activation was attenuated, but still resulted in a pronounced induction of MAD2 protein 
(Figure 7b). 
 
5.2 c-MYC binds to human MAD2 and BubR1 promoters in vivo 
Examination of the human MAD2 (MAD2L1) promoter revealed the presence of 
two canonical E-box sequences, which represent putative c-MYC binding sites, 
separated by 90 base pairs in the first intron (Figure 8a). Chromatin-
immunoprecipitation (ChIP) analysis confirmed in vivo binding of c-MYC to the E-
boxes in the first intron of the human MAD2 gene, whereas a region located ~6 kbp 
downstream in the 4th intron was not bound by c-MYC (Figure 9a). Enrichment of the 
fragment amplified from the first intron of MAD2 was detected after activation of a 
conditional c-MYC allele. As a positive control, promoter occupation by c-MYC was 
also detected for the known c-MYC target gene CAD.  
The promoter element of the BubR1 gene was also investigated for the 
presence of E-boxes, where one E-box was found in the first intron in close proximity 
to its transcriptional start site (Figure 8b). Using the same conditions as for MAD2 
ChIP analysis, it was confirmed that c-MYC occupies this site in vivo (Figure 9a), 
whereas a region located ~10 kbp upstream of the promoter was not bound by c-MYC 
(data not shown). Therefore, c-MYC directly regulates MAD2 and BubR1 expression.  
Both MAD2 and BubR1 promoter regions in mouse and rat also contain several 
E-boxes. However, positions of these E-boxes were not conserved between species 
(Figure 8, a and b). A similar divergence in the positioning of E-boxes has been 
described for bona fide c-MYC target genes (Haggerty et al., 2003).  
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Figure 8 The positions of E-boxes in the human, rat and mouse MAD2 and BubR1 
genes 
 
(a) MAD2 (=MADL1) and (b) BubR1 E-box elements are indicated relative to the transcriptional start 
site (TSS; arrow). Exons are represented by rectangles. Protein coding sequences are shaded in grey. 
Arrow heads represent the position of oligonucleotides used for ChIP analysis. 
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Fugure 9 Detection of c-MYC occupancy at the human MAD2 and BubR1 promoters 
 
(a)   Chromatin-immunoprecepitation (ChiP) of MAD2 promoter element was performed on PJMMR1 
cells. PJMMR1 cells were starved for 72 hours (0.05% FCS) and then restimulated with 15% FCS and 
doxycycline (1 µg/ml) for 16 hours. Cells were subjected to chromatin immunoprecipitation (ChIP) 
analysis. For details see Methods. Enrichment of DNA fragments bound by c-MYC was determined by 
qPCR of a region encompassing the two E-boxes in the first intron of MAD2. E-box containing 
fragments in the CAD promoter served as a positive control, MAD2 intron 4 as negative controls. (the 
analysis was performed by Dr. Berlinda Verdoot, MPI of Biochemistry). (b) Chromatin-
immunoprecepitation (ChiP) of BubR1 promoter element was performed using PJMMR1 cells. Relative 
enrichment of the E-box amplicon derived from the first BubR1 exon was determined by qPCR. As 
reference an amplicon on 16q22 devoid of E-boxes was used. Depicted is the average of two 
experiments with error bars indicating the standard error. 
 
5.3 c-MYC induces a mitotic delay 
The MAD2 and BubR1 proteins transmit a “wait signal” from kinetochores not 
properly attached to the spindle apparatus which inhibits the APC/cyclosome and 
prevents the premature onset of anaphase (Musacchio and Hardwick, 2002). To 
monitor the effects of c-MYC activation on the progression through mitosis or 
chromatin behavior two c-MYC inducible cell lines were generated (DLD-1-tTA-MYC).  
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Figure 10 Effects of c-MYC induction on mitotic phases in the presence of MAD2 or 
BubR1 knockdown 
 
Representative examples of cells progressing through mitosis in the presence or absence of c-MYC 
activation. DLD-1 cells harboring a conditional c-MYC allele and expressing H2B-YFP were monitored 
by time-lapse microscopy 36 hours after activation of c-MYC. Time points are indicated above the 
frames in minutes. Cell pools stably expressing shRNAs directed against MAD2, BubR1 or non-
silencing shRNAs (sh-control) were compared. DLD-1-tTA-MYC cells were cultured in the presence of 
100 ng/ml of DOX. For activation of c-MYC DOX was removed. 
 
(Figure 10) and PJMMR1 (data not shown) stably expressing yellow and green 
fluorescent protein (YFP/GFP)-tagged histone H2B protein, respectively. To determine 
the length of mitosis after c-MYC activation these cells were subjected to time-lapse 
microscopy (Figure 12 and 13). A large fraction of mitotic events in DLD-1-tTA-MYC 
cells displayed a significant extension after activation of c-MYC, in comparison to 
PJMMR1. A similar extension of mitosis length by c-MYC was found in DLD-1, 
PJMMR1 or hDF-MYCER cells not expressing H2B fusion proteins (data not shown) 
and in hDF constitutively expressing c-MYC (Figure 16c). In order to determine 
whether the c-MYC-induced increase in MAD2 or BubR1 expression mediates the c-
MYC-induced mitotic delay the levels of the MAD2 and BubR1 proteins were limited 
by stable expression of retroviral constructs mediating MAD2- or BubR1-specific RNA 
interference (Figure 7). These analyses were performed with two different short-
hairpin RNA (shRNA) encoding constructs targeting the same mRNA to exclude off-
target effects (n1 and n2). As a control cells expressing a non-silencing shRNA were 
generated (sh-control). 
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Figure 11 Western blot analysis of MAD2 and BubR1 protein downregulation in DLD-
1-tTA-MYC and PJMMR1 cell lines.  
 
(a)     Downregulation of MAD2 protein by stable expression of a MAD2-specific short-hairpin RNA 
(shMAD2) in DLD-1-tTA-MYC cells was confirmed by Western blot analysis. c-MYC was induced for 48 
hours. (b) Downregulation of BubR1 protein level in DLD-tTA-MYC stably expressing BubR1-specific 
short-hairpin RNA (shBubR1) cells was confirmed by Western blot analysis. c-MYC was induced for 48 
hours. PJMMR1 cells stably expressing a short RNA hairpin directed against (c) MAD2 or (d) BubR1 
were subjected to Western blot analysis. c-MYC was induced for 48 hours. 
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Figure 12 Determination of the length of different mitotic phases after activation of 
ectopic c-MYC in DLD-tTA-MYC and PJMMR1 cells 
 
After activation of c-MYC for 36 hours DLD-tTA-MYC and PJMMR1 cells were subjected to time-laps 
recording for 18 hours. Each bar represents 100 mitotic events. 
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Figure 13 Determination of mitotic length after activation of ectopic c-MYC in DLD-
tTA-MYC and PJMMR1 cell lines 
 
The evaluation of the mitotic length after c-MYC activation in DLD-tTA-MYC and PJMMR1 cells. 
Counting is based on results obtained for Figure 12. Each bar represents 100 mitotic events. 
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For each genotype and state 100 mitotic events recorded by time-lapse microscopy 
were analyzed in detail. Representative examples are shown in Figure 6. DLD-1 cells 
required on average ~65 minutes from the first signs of nuclear envelope breakdown 
until completion of cytokinesis. However, after activation of ectopic c-MYC ~95 
minutes were required for passage through mitosis. After down-regulation of MAD2 by 
constitutive shRNA expression the c-MYC-induced extension of mitosis was 
significantly reduced (Figure 12a and 13a). Therefore, the c-MYC-induced mitotic 
delay is mediated, at least in part, by the c-MYC-mediated induction of MAD2 
expression. Also the down-regulation of BubR1 diminished the c-MYC-induced mitotic 
delay by shortening the prolonged mitosis (Figure 13). We observed a higher 
efficiency in the down-regulation of BubR1 protein expression by the BubR1-specific 
shRNA n2 versus the n1 shRNA (Figure 11b). This presumably caused a more 
pronounced reversion of the c-MYC-induced delay by the n2-shRNA, indicating a 
dependence of the mitotic delay on the concentration of BubR1. The effects of c-MYC 
activation and inhibition of MAD2 and BubR1 were restricted to prometaphase (Figure 
12, a and b).  
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Figure 14 Distribution of mitotic durations after c-MYC activation 
 
Distribution of mitotic length after c-MYC activation in DLD-1-tTA-MYC cells exhibiting down-regulation 
of (a) MAD2 or (b) BubR1 by RNA interference. One graph represents 100 mitotic events. 
 
  
46 
 
 
shcontrol
0
5
10
15
20
25
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270
duration of mitosis [min]
nu
m
be
r o
f m
ito
tic
 c
el
ls
 - c-Myc
+ c-Myc
shMAD2 n1
0
5
10
15
20
25
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200
duration of  mitosis [min]
nu
m
be
r o
f m
ito
tic
 c
el
ls  - c-Myc
+ c-Myc
shMAD2 n2
0
5
10
15
20
25
30
50 60 70 80 90 100 110 120 130 140 150
durat r ion of  mit osis [ min]
nu
m
be
r o
f m
ito
tic
 c
el
ls
 - c-Myc
+ c-Myc
shcontrol
0
5
10
15
20
25
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280
duration of  mitosis [min]
nu
m
be
r o
f m
ito
tic
 c
el
ls
 - c-MYC
+ c-MYC
shBubR1 n1
0
5
10
15
20
25
30
35
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200
duration of mitosis [min]
nu
m
be
r o
f m
ito
tic
 c
el
ls
 - c-MYC
+ c-MYC
shBubR1 n2
5
10
15
20
25
30
nu
m
be
r o
f m
ito
tic
 c
el
ls
0
50 60 70 80 90 100 110 120 130 140 150
duration of mitosis [min]
 - c-MYC
+ c-MYC
PJMMR1
a
b
 
Figure 15 Distribution of mitotic durations after c-MYC activation 
 
Distribution of mitotic length after c-MYC activation in PJMMR1 cells exhibiting down-regulation of (a) 
MAD2 or (b) BubR1 by RNA interference. One graph represents 100 mitotic events. 
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Figure 16 c-MYC induces MAD2 and BubR1 and mitotic delay in primary human 
diploid fibroblasts 
 
(a) Western blot analysis of c-MYC and MAD2 protein expression in primary hDFs and hDFs 
immortalized by c-MYC or hTert expression. (b) Distribution of mitotic durations in the population of 
hDFs immortalized by c-MYC or Tert in comparison to non immortal hDFs with a passage 20. For each 
cell type 25 mitotic events recorded by time-lapse video-microscopy were evaluated. (c) Evaluation of 
distribution of mitotic phases in hDF constitutively expressing the indicated genes. pro-meta: sum of the 
length of prophase, prometaphase and metaphase, ana-telo: sum of anaphase and telophase, sum: 
length of whole mitosis.  
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The number of cells displaying extremely delayed mitosis (more than 100 
minutes) was relatively low (Figure 14). When MAD2 or BubR1 was down-regulated 
by RNA interference the increased variation in the length of mitotic events observed 
after c-MYC activation was reversed towards the smaller range observed in DLD-1 
cells without c-MYC activation (Figure 14).  
Similar analyses were performed in the aneuploid breast cancer cell line MCF7. 
The MCF7-derived PJMMR1 cells showed a c-MYC-induced mitotic delay and 
reversion after knock-down of MAD2 and BubR1 (Figure 13, c and d, 14, c and d). 
However, in these cells the variations in the mitotic length as well as the reversal of 
the delay by knock-down of MAD2 or BubR1 expression were more pronounced than 
in DLD-1 cells (Figure 14, c and d, 15). 
In the population of DLD-1-tTA-MYC and PJMMR1 (data not shown) cells were 
observed a number of mitotic and chromatin abnormalities (Figure 17) which 
correlated with the duration of c-MYC activation (Figure 18, a). Initially, c-MYC 
overexpression increased abnormal meta-anaphase transition and led to distortion of 
metaphase plate formation (Figure 17, b and c). Presumably, these alterations, 
together with additional effects, like lagging chromosomes, chromatin bridges or 
micronuclei formation (Figure 17, d, e, f, g and h) resulted in the extension of mitotic 
length (Figure 18, b). Furthermore, extended mitotic events were frequently followed 
by synchronous post-mitotic apoptosis of two daughter cells (Figure 17, k, and 18, c).    
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Figure 17 c-MYC activation leads to mitotic abnormalities, chromosomal 
perturbations, genomic instability and induction of post-mitotic apoptosis 
 
(a) Example of normal meta-anaphase transition and formation of a proper metaphase plate. (b) Meta-
anaphase transition with defused metaphase plate. (c) Prometa-anaphase transition. Metaphase plate 
does not form. Lagging chromosomes in (d) meta- or in (e) anaphase. Formation of chromosomal 
bridges throughout (f) anaphase and (g) telophase. (h) Micronucleus formation. (k) Synchronous 
apoptosis of two daughter cells following of mitotic division (post-mitotic apoptosis).   
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Figure 18 c-MYC-induced chromatin abnormalities and post-mitotic apoptosis wich 
are associated with extended mitosis 
 
(a) DLD-tTA-MYC cells were recorded for 18 hours after activation of c-MYC for 24 and 48 hours. The 
graph represents the percentage of mitotic events resulting in post-mitotic apoptosis. For the 24 and 48 
hour time-point 150 and 222 mitotic events were analyzed, respectively. Distribution of mitotic length of 
cells displaying (b) chromatin abnormalities or (c) post-mitotic apoptosis after c-MYC activation in DLD-
tTA-MYC cells. Grey bars represent cells which showed a mitosis duration also found in cells without c-
MYC activation, black bars represent cells with extended mitotic durations.  
 
 
5.4 Synchronous apoptosis in cells with delayed mitosis 
The time-lapse recording allowed to distinguish different forms of c-MYC-
induced apoptosis and characterize them as random single cell apoptosis and post-
mitotic apoptosis, which represents approximately 30% and 70% of whole apoptosis 
fraction respectively (Figure 19b). Further analysis of the fraction of cells undergoing 
post-mitotic apoptosis revealed a number of interesting details. First of all, this fraction 
increased with time after c-MYC activation and reached ~15 and ~22 % of the 
population of dividing cells observed in the time-laps movies by the day 1 and 2 of c-
MYC activation respectively (Figure 18a and 19a).  
Interestingly, the time-point of apoptosis initiation was identical in the two 
daughter cells and in average has approximately four hours between the end of the 
anaphase and beginning of chromatin cleavage and condensation accepted as the 
beginning of late apoptotic processes. This synchronicity suggested that an initiating 
event took place before cell division, which primed the cells for apoptosis. Additional 
results suggest that this event could be the induction of DNA damage by c-MYC 
during S-phase in the parental cell (data not shown). This form of post-mitotic 
apoptosis was blocked by addition of a caspase 3 inhibitor (data not shown). As DLD-
1 cells express mutant p53, this c-MYC-induced post-mitotic apoptosis is p53-
independent. DLD-1 cells with RNA-interference mediated down-regulation of BubR1, 
but not cells with reduced levels of MAD2, showed a decrease of post-mitotic 
apoptosis after activation of c-MYC by ~20% (Figure 19c). Therefore, BubR1 may be 
involved in the induction of this form of apoptosis. 
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Figure 19 c-MYC-induced mitotic delay is followed by synchronous apoptosis  
(a) Representative example of a time-lapse sequence showing a post-mitotic apoptosis after activation 
of c-MYC in H2B-YFP expressing DLD-tTA-MYC cells. Time-points (minutes) are indicated above the 
frames. (b) The types of apoptosis events were observed: single cells undergoing apoptosis and 
synchronous apoptosis of two daughter cells, post-mitotic apoptosis. Observation based on evaluation 
of 100 apoptotic events acquired by time-lapse microscopy from DLD-1-tTA-MYC cells after 36 hours of 
c-MYC activation. (c) Influence of RNA interference mediated down-regulation of MAD2 or BubR1 
proteins on the frequency of mitotic events resulting in post-mitotic apoptosis after activation of c-MYC 
in DLD-tTA-MYC cells. For each genotype at least 200 mitotic events were evaluated. The frequency of 
mitosis resulting in synchronous apoptosis in cells expressing control sh-RNAs was set to 100%.  The 
average of two independent experiments is depicted.   
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5.5 c-MYC induces CIN in MIN cell lines 
DLD-1 cell are mismatch repair deficient and therefore display MIN. As most MIN cell 
lines, DLD-1 cells are diploid and have an intact SAC (Cahill et al., 1998). To 
determine extend of c-MYC-induced chromosomal instability micronuclei formation 
was quantified. Micronuclei represent acentric fragments or whole chromosomes not 
properly integrated into one of the two daughter nuclei during mitosis. After c-MYC 
activation a gradual increase in the frequency of cells with micronuclei was observed 
(Figure 20b). After eight days the frequency of cells with micronuclei had increased 
from 4% to more than 10% (p<0.001). The induction of CIN after activation of ectopic 
c-MYC was confirmed by interphase-FISH analysis of chromosome 8 and 17 (Figure 
20c). After eight days of c-MYC activation, the percentage of cells with aberrant 
number of signals had increased from 1.4% (chromosome 8) and 1.8% (chromosome 
17) to 3.9% and 4.5%, respectively (p<0.001). Therefore, the increase of numerical 
aberrations detected for chromosome 8 and 17 paralleled the increase in 
micronucleus formation. The frequency of micronuclei and the degree of CIN as 
detected by interphase FISH without c-MYC activation was in line with previously 
described basal levels of aneuploidy in DLD-1 cells (Lengauer et al., 1997).  
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Figure 20 Analysis of c-MYC-induced CIN  
 
(a) Examples of micronucleus formation (white arrows) 8 days after activation of c-MYC in DLD-tTA-
MYC cells. Some micronuclei contain centromeric signals for chromosome 8 (green) and 17 (red). (b) 
The frequencies of micronucleus formation were determined microscopically at the indicated time points 
after activation of c-MYC in DLD-1-tTA-MYC cells. For each time point at least 600 nuclei were 
analyzed and differences in micronuclei percentages between -/+ c-MYC cells were highly significant 
for each time point as determined by the Chi-square test (p < 0.005). (c) Summary of results obtained 
by FISH analysis. At least 600 nuclei were analyzed at each time point and the difference in the 
percentage of cells with aberrant signals was highly significant after eight days of c-MYC activation (p < 
0.001). (experiments were performed by Dr. Nils Hartmann, MPI of Biochemistry) (d) Determination of 
micronucleus frequencies. For each cell type ~1000 cells were evaluated. (e) FISH analysis of 
chromosome 8 and 17 using the centromeric probes shown in (c). ~600 nuclei of each cell line were 
analysed. (experiments were performed by Dr. Nils Hartmann, MPI of Biochemistry) 
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Figure 21 c-MYC-induced micronuclei formation in DLD-1-tTA-MYC and PJMMR1 
cells is not influenced by the levels of MAD2 and BubR1 expression 
Analysis of c-MYC-induced formation of micronuclei in DLD-tTA-MYC cells in the presence of RNA 
interference down-regulating MAD2 (a) or BubR1 (b) expression. Samples were fixed at the indicated 
time points. Each bar represents at least 1000 cells derived from several independent fields. Analysis of 
c-MYC-induced micronucleus formation in PJMMR1 cells in the presence of RNA interference down-
regulating MAD2 (c) or BubR1 (d) expression. Each bar represents at least 1000 cells derived from 
several independent fields. 
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An increase in the frequency of micronuclei and numerical chromosome aberrations 
was also observed after activation of c-MYC in the MCF-7 derived aneuploid breast 
cancer cell line PJMMR1 (Figure 21, c and d; data not shown) and in primary human 
diploid fibroblasts stably expressing ectopic c-MYC (Figure 20, d and e). 
  
5.6 Analysis of putative mediators of c-MYC-induced CIN  
Alterations in protein expression of both MAD2 and BubR1 and some other 
components of spindle checkpoint machinery were previously linked to chromosomal 
instability (Dobles et al., 2000; Shin et al., 2003). Stable expression of shRNA was 
used to determine whether the down-regulation of MAD2 or BubR1 by RNA 
interference would not only affect progression through mitosis, but also leads to a 
decreased number of micronuclei as a measure of CIN. However, the frequency of 
micronuclei observed after c-MYC activation in DLD-1-tTA-MYC and PJMMR1 cells 
was not significantly altered in cells with MAD2 or BubR1 down-regulation (Figure 20).  
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Figure 22 Evaluation of microtubule spindle numbers after activation of c-MYC in 
DLD-1-tTA-MYC and PJMMR1 cells 
 
(a) Determination of microtubule spindle number upon activation of c-MYC in DLD-1-tTA-MYC and 
PJMMR1 cells. Cells were cultured on cover slips in the presence or absence of DOX to control c-MYC 
expression. Then they were fixed and stained with antibody to γ-tubulin to visualize microtubule 
spindles (yellow) by immunofluorescence. (b) The percentage of spindles with 4 poles was evaluated 
in a population of mitotic cells after c-MYC activation. 
 
Furthermore, the rate of c-MYC-induced increase of aberrant microtubule spindles 
lagged behind the formation of micronuclei (Figure 22). Therefore, the increased rate 
of aneuploidy observed after activation of c-MYC was presumably not due to induction 
of aberrant spindle formation or deregulation of MAD2 or BubR1 expression. 
 
5.7 Construction of episomal vectors for RNA interference 
Recently, comprehensive libraries of microRNAs which were designed to facilitate the 
RNA interference mediated down-regulation of all human or mouse genes have been 
described (Silva et al., 2005). These microRNAs are publicly available and are 
provided in the pSHAG-MAGIC 2c (pSM2c) retroviral vector, which provides 
constitutive expression driven by a long terminal repeat (LTR). pRTS-1 was chosen as 
a basis expression vector with a number of convenient features bearing in one 
plasmid, including following: bi-directional CMV-based promoter (Ptetbi-1) expressing 
fluorescent tracing protein (RFG/GFP) and transcript of interest in DOX-dependent 
maner; bicestronic expression cassette under control of chicken beta actin promoter 
encodes for highly DOX-sensitive reverse tetracycline controlled transactivator rtTA2S-
M2 and a Tet repressor-KRAB fusion protein (tTSKRAB); selection marker 
(Hygromycin/Puromycin); oriP and EBNA-1 expressing cassette to maintain the 
plasmid episomaly.  
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Figure 23 Generation of episomal vectors for conditional expression of 
microRNAs 
 
Flow chart showing the steps necessary to generate pEMI-vectors harboring microRNA cassettes. 
Abbreviations: AmpR: ampicillin resistance; CmR: chloramphenicol resistance; EBNA-1: EBV nuclear 
antigen required for Ori P function; EBV: Epstein-Bar virus; H2R: homology 2 region; Hyg B: 
hygromycin B; LTR: long terminal repeats; MAGIC: mating-assisted genetically integrated cloning; miR-
30: precursor microRNA; mRFP: monomeric red fluorescent protein; OriP: EBV origin of replication, 
pEMI: plasmid for episomal microRNA expression; pheS: phenylalanine synthase relaxed-specificity 
allele Gly294; PPGK: PGK-promoter; pSHUMI: plasmid for shuttling of microRNAs, pSM2c: pSHAG-
MAGIC 2c retroviral vector for microRNA expression; Ptet-bi-1: bidirectional tet-responsive promoter; 
rtTA2S-M2: reverse tetracycline controlled transactivator; tTSKRAB: tetracycline repressed silencer.  
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Several microRNA cassettes have been taken from the library or were newly 
designed to transfer to the pRTS-1 vector. Since pRTS is a relatively large vector 
(~18 kbp) the intermediate pUC19-based shuttle vector pSHUMI (plasmid for shuttling 
microRNAs) is necessary for the transfer procedure (Figure 23). For a faster transfer 
of microRNAs, pRTS vector was adapted to the ligation-free MAGIC technique 
(mating-assisted genetically integrated cloning)(Baek et al., 2005). The resulting 
pEMI (plasmid for episomal microRNA expression; Figure 23) harbors a pheS Gly294 
allele encoding a tRNA synthase for phenylalanine with relaxed specificity, which 
incorporates toxic chloro-phenylalanine and thereby facilitates selection against non-
recombinant clones. Bacteria containing the pEMI-recipient vector were conjugated 
with bacteria containing a pSM2c vector encoding a p53-specific microRNA. 79 of 80 
(98.7%) of the resulting bacterial colonies harbored pEMI vectors containing the p53-
microRNA as determined by colony PCR (data not shown). Successful recombination 
was also confirmed by restriction and sequence analysis (data not shown). 
 
5.8 Functional evaluation of pEMI vectors 
The human osteosarcoma cell line U2OS was transfected with pEMI vectors 
encoding either MAD2-, p53-specific or non-silencing microRNAs, which do not 
recognize any human mRNA. Selection for cells containing the pEMI vectors with 
hygromycin B was completed within 7 days. The resulting pools of resistant cells 
were analyzed for RT-PCR analysis to determine the expression of the ectopic 
microRNA after addition of doxycycline (DOX) (Figure 24). In the absence of DOX no 
MAD2-specific microRNA was detected after 30 PCR cycles. However, 24 hours after 
addition of DOX the microRNA was expressed. By 48 hours the expression increased 
further as determined by quantitative PCR (data not shown). As no microRNA 
expression was detected in the absence of DOX, these results show that the pEMI 
vectors mediate an extremely stringent control over microRNA expression. In line with 
this observation the cell pools were consistently devoid of mRFP (monomeric red 
fluorescent protein) expression in the absence of DOX as determined by live cell 
fluorescence microscopy (Figure 24b). 
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Figure 24 Conditional microRNA expression mediated by pEMI 
 
(a) RT-PCR analysis of microRNA expression. U2OS cells stably transfected with pEMI encoding a 
Mad2-specific or non-silencing microRNA (miRNA) were treated with 200 ng/ml DOX for 24 or 48 
hours. The experiment was performed in duplicates. After 30 cycles of PCR DNA fragments were 
separated either on 15% poly-acryl-amid gels (for detection of the Mad2-specific miRNA precursor) or 
2% agarose gel (for β-actin). DNA-markers in outer lanes: 10 bp ladder (upper panel) and 100 bp 
ladder (lower panel). (b) Detection of monomeric red fluorescent protein (mRFP) expression 24 hours 
after addition of the indicated doxycycline (DOX) concentrations to U2OS cells transfected with pEMI 
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vectors encoding p53-specific miRNAs. Exposure times: 500 ms for mRFP, 50 ms for phase contrast. 
(c) Doxycycline (DOX) dose-reponse of p53 conditional knock-down: U2OS cell pools stably 
transfected with pEMI-p53miRNA plasmid were treated with the indicated DOX concentrations for 24 
hours (upper panel). Control cells are also shown (middle panel). pEMI-MAD2miRNA-mediated down-
regulation of MAD2 expression (lower panel). (Experiments with p53-specific microRNA were 
performed by Peter Jung, MPI for Biochemistry). 
 
   Within 24 hours after addition of DOX approximately half of the cells were positive 
for mRFP at 3.2 ng/ml DOX and virtually all cells were positive at 25 ng/ml (Figure 
24b). Efficiency of protein down-regulation depends on number of factors including 
stability and turnover of the targeted mRNA/protein.  
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Figure 25 MAD2 knockdown sensitizes to spindle poison.  
Fluorescence activated cell sorting (FACS) analysis of U2OS cells stably transfected with pEMI-
MAD2miRNA or pEMI non-silencing-miRNA plasmids. Cells were cultured in 100 ng/ml DOX for 4 days 
and colcemid (25 µg/ml) was added 24 hours before harvesting  
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The pEMI microRNA expressing system markedly down-regulated the level of p53 
protein already at concentrations of DOX between 0.8-1.6 ng/ml (Figure 24c). The 
most pronounce effects were observed in the range of 6.2-50 ng/ml with both MAD2 
and p53 proteins. Induction of a non-silencing microRNA did not affect the levels of 
p53 protein.  
As an example for the inactivation of an essential gene by the system 
introduced here we conditionally down-regulated the expression of the MAD2 protein, 
which was shown to result in mitotic failure and extensive cell death when 
permanently inactivated (Hernando et al., 2004; Kops et al., 2004). After introduction 
of the pEMI-plasmid encoding a MAD-specific microRNA we observed no effect on 
the viability and cell cycle distribution. Only when MAD2 was down-regulated by 
addition of DOX an increased fraction of apoptotic cells was observed. Treatment 
with colcemid, a drug depoliymerizing spindle microtubules and thereby inactivating 
spindle formation during metaphase, led to increased apoptosis. In the presence of 
MAD2 knockdown this phenotype was again more pronounced. These results show 
that the expression of microRNAs can be tightly controlled using pEMI vectors, which 
are therefore useful for studying essential genes. Another example shows that p53 
microRNA mediated knockdown prevents any significant increase in p53 and p21 
protein level after DNA damage and p53 inhibited arrest in the G1-phase, both 
caused by etoposide (Jung et al., 2007 PNAS paper). 
To rule out activation of the interferon system by the pEMI vector-driven 
microRNA expression, we analysed the expression of the IFIT1 (interferon-induced 
protein with tetratricopeptide repeats 1) gene by quantitative PCR (qPCR). Others 
have shown that expression of IFIT1 mRNA is rapidly induced upon interferon (IFN) 
treatment (Kusari and Sen, 1986). Besides interferon, double stranded RNA (dsRNA) 
and viral infection have been shown to increase the expression of IFIT1 (Guo et al., 
2000). pEMI-driven expression of a non-silencing microRNA for 2 and 4 days did not 
provoke an increased IFIT1 expression (Figure 26). Also expression of a p53-specific 
microRNA did not lead to any increase in IFIT1 expression, whereas transfection of 
U2OS cells with a synthetic double stranded RNA (poly I:C) led to a ~40-fold increase 
in IFIT1 mRNA expression within 18 h after transfection. Incubation of U2OS cells in 
media containing poly I:C also increased the level of IFIT1 up to ~7-fold (data not 
shown) indicating this cell line is in principle very sensitive towards the presence of 
dsRNA. 
  
63 
 
 
 
0
10
20
30
40
50
60
70
fo
ld
in
du
ct
io
n
of
 IF
IT
1
m
R
N
A
0           2           4           C      poly-IC
non-silencing microRNA
p53 microRNA
poly-I:C transfection
induction of microRNA
expression
[days with DOX]
 
Figure 26 pEMI-driven microRNA expression does not elicit a dsRNA response 
 
qPCR analysis of IFIT1 (interferon-induced protein with tetratricopeptide repeats 1) expression after 
induction of microRNAs or treatment with poly I:C. U2OS pools were treated with 100 ng/ml DOX for 
the indicated time periods to induce non-silencing or a p53-specific microRNA driven by pEMI vector. 
As a positive control for IFIT1 gene induction, U2OS cells were transfected with poly I:C dsRNA (IC) or 
subjected to a mock transfection (C) for 18 h. Shown are the relative expression levels of IFIT1 
normalized to β-actin expression. IFIT1 expression levels in untreated or MOCK transfected cells were 
set to 1. All experiments were performed in triplicates. Error bars indicate standard deviations. 
(Analyses was performed by Peter Jung, MPI of Biochemistry). 
 
 
 
Furthermore, proliferation assays showed no significant anti-proliferative effect of 
pEMI-driven microRNA over-expression and cells were viable for several weeks when 
expressing microRNAs not targeting essential genes, whereas treatment with poly I:C 
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led to an apoptotic response 2 days post transfection presumably by activating the 
dsRNA response (data not shown). Taken together, expression of ectopic microRNA 
by pEMI vectors does not lead to a dsRNA response or other toxic side effects. 
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6. Discussion 
 
6.1 c-MYC-induced genomic instability 
The induction of genomic instability by c-MYC activation has been repeatedly 
described in the literature (Felsher and Bishop, 1999; Louis et al., 2005; Mai et al., 
1996a; Mai et al., 1996b; Vafa et al., 2002; Yin et al., 2001)). A number of 
observations suggested a pivotal role of c-MYC activation to drive cell cycle by 
exaggeration of intrinsic processes. Activation of cyclins and repression of CDK 
inhibitors together with ability to escape p53/p21 checkpoint machinery give an 
advantage for c-MYC overexpressing cells to maintain unrestricted proliferation. 
Oncogenic c-MYC expression in this context may cause DNA damage by different 
means. In the presence of oncogenically generated damaged DNA, c-MYC may drive 
cells through cell cycle by overriding p53/p21 dependent arrest (Hermeking and Eick, 
1994; Seoane et al., 2002), which may result in genomic destabilization. Such model 
describes a case of temporary activated c-MYC after first hours-days of activation 
(Bartek and Lukas, 2001b). On the later time periods of days-weeks, genomic 
instability initiated by c-MYC overexpression leads to clonal selection of cells with 
intact checkpoint pathways or acquiring genetic alteration allowing c-MYC 
independent proliferation (Karlsson et al., 2003), and has a similarity with so called 
effect of tumor relapsation after inactivation of conditional c-MYC expression (Arvanitis 
and Felsher, 2006; Pelengaris et al., 2002a). Additionally, c-MYC overactivation can 
directly lead to chromosomal structure alterations through gene amplification and 
telomere remodeling.  
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Figure 27 Exaggeration of cellular pathways and mechanisms by c-MYC 
overactivation cause genomic instability.  
(a) Common cellular pathways and mechanisms affected by c-MYC. (b) Principal cellular processes 
initiated by c-MYC overactivation. (c) c-MYC caused genomic destabilization at two distinct levels 
leading either to changes of chromosome number such as aneuploidy and endo-reduplication or 
defects in chromosomal integrity including chromosomal breaks, fusions or translocations. Genomic 
instability furthermore could give an advantage for tumor initiation or progression. 
 
In the studies presented here the activation of c-MYC expression results in 
comparable features and signs of unstable chromatin behavior. Conditional c-MYC 
activation in DLD-1 and MCF-7 cells leads to chromosomal instability measured by 
centromere probes hybridization or micronuclei counting. Furthermore, an increase of 
DNA damage as detected by γ-H2AX/53BP1 staining was observed (Menssen et al., 
2007). By time lapse imaging of living cells abnormal transition and chromosome 
behavior throughout prometa-, meta- and anaphases was observed, which was 
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accompanied by distortion of the metaphase plate. c-MYC activation leads to elevation 
of mitotic events with disorganized metaphase plate structure. On chromatin level, c-
MYC causes appearance of lagging chromosomes and chromatin bridges throughout 
anaphase and in following interphase. In some cases chromatin bridges led to fusion 
of two daughter cells and appearance of tetraploid cells. Breaks of bridges and 
improper separation of lagging chromosomes in anaphase generated daughter cells 
with unequally distributed genetic material due to loss or gains of chromosomes. Such 
c-MYC-dependent induction of chromatin abnormalities might potentially be explained 
by passaging of damaged DNA through G2 checkpoint into mitosis (Syljuasen et al., 
2006). c-MYC overexpression induces DNA damage and by abrogating the G1/S 
checkpoint may push cells with partially repaired or unrepaired DNA into the G2 phase 
(Bartek and Lukas, 2001b; Sheen and Dickson, 2002). In several cellular models c-
MYC overexpression was shown to attenuate G2 arrest (Sheen et al., 2003) and in the 
absence of active p53 pathway even efficiently overcome it (Yin et al., 2001; Yin et al., 
1999). In some cellular systems c-MYC leads to attenuation of G2 phase. In some 
cases extension exist even until beginning of prophase-like stage. Additionally we 
observed appearance of γ-H2AX foci on mitotic chromosomes, associated with c-MYC 
induction (data not shown). This might suggest that activated c-MYC allow G2 arrested 
cells with damaged DNA to proceed into mitosis or the following S-phase, initiating 
endo-reduplication (Figure 28). Furthermore, in earlier stages of mitosis damaged, 
incompletely or improperly unrepaired DNA may become packaged into the 
chromosomes, which lead to formation of breaks and chromatin bridges in the follwing 
mitosis. All chromosomes have to be rearranged throughout mitosis to give an equal 
separation of genetic material into two daughter cells. However, those damaged 
chromosomes could cause attenuation and abnormal mitotic progression observed in 
time-lapse video that finally could leads to aneuploidy (Mikhailov et al., 2002). 
Furthermore, cells with severe DNA damage or chromosomal abnormalities may be 
eliminated from the population via apoptosis (Figure 28) (Gasser and Raulet, 2006).  
How oncogenic c-MYC overexpression directly leads to DNA damage is not 
clear (Mai and Mushinski, 2003; Wade and Wahl, 2006). One potential explanation is 
the generation of ROS by c-MYC (Vafa et al., 2002) which causes DNA damage. 
Recently it was shown that c-MYC can induce double-stranded breaks, independently 
on ROS induction (Ray et al., 2006). Other potential effects of c-MYC activation might 
be the distortion of replication processes (Angus et al., 2002; Blagosklonny and 
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Pardee, 2002; Matsumura et al., 2003; Spruck et al., 1999; Walter et al., 1998), 
leading to improper replication followed by DNA breaks (Lengronne and Schwob, 
2002).          
                 
6.2 c-MYC-induced mitotic delay 
Results of this study show that c-MYC induces the expression of both BubR1 
and MAD2 on the level of RNA and protein. These proteins inhibit CDC20-APC/C and 
progression into anaphase until all kinetochore are properly attached to microtubule 
spindles of opposite poles (Kops et al., 2005). In accordance with the literature, 
upregulation of these proteins mediated by c-MYC leads to extension of mitosis length 
at specifically stage – prometaphase, where both proteins have their main function 
(Hernando et al., 2004; Li et al., 1999). Modulation of gene expression using stable 
expression of shRNA constructs against either BubR1 or MAD2 blocked efficient 
upregulation of proteins by c-MYC induction and as following, decreased average 
length of mitosis. Interestingly, MAD2 protein downregulation in the presence of 
activated c-MYC has only partial effect on mitosis length, where BubR1 knockdown 
almost completely reversed this phenotype. Downregulation of BubR1, which is a 
transducer of ‘’wait anaphase signal’’ through MAD2 and forms an inhibitory complex 
of CDC20 together with MAD2, may therefore more efficiently influence signal 
transduction then downregulation of final signalling effector MAD2 (Figure 3).  
The potential biological purpose of the activation of BubR1 and MAD2 by c-
MYC is an increased sensitivity of the spindle checkpoint machinery to recognize 
abnormal chromosomal organization and with following extension of prometaphase to 
give a time for chromosome reorganization, to ensure proper propagation of genome 
during cell division (Hernando et al., 2004). Probably due to the same reason to 
propagate intact genome c-MYC activates multiple genes involved in DNA repair when 
quiescent cells re-enter cell cycle (Menssen and Hermeking, 2002; Patel et al., 2004).   
This observation gives rise to the questions whether the induction of BubR1 
and MAD2 spindle checkpoint genes by c-MC can directly lead to lengthening of 
mitosis or depends on DNA damage passaging through G2 checkpoint into mitosis. 
From one side chromosomes which contain DNA damage lesions could directly 
activate spindle checkpoint and extend mitosis (Menssen et al, 2007). Results of this 
study show that population of cells with chromatin abnormalities in mitosis associated 
with extended mitotic length, but the average mitotic length in this population only by 
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10 minutes more in comparison to population of cells without visible alterations (data 
not shown). Therefore, the c-MYC-induced DNA damage would only partially explain 
the mitotic delay. Furthermore, it would be interesting to prove whether after active 
ATM signalling in the cells with DNA damage overcomes G2 arrest might influence on 
spindle checkpoint and if it does, how it modulate the activity. ATM signalling already 
was shown to influence mitotic progression in several ways: through downregulation of 
centrosome function (Sibon et al., 2000), Plk1 activity (Smits et al., 2000) and cyclin A 
degradation (Su and Jaklevic, 2001). 
 
6.3 BubR1/MAD2-dependent mitotic delay does not influence c-MYC-induced 
genomic instability 
Another question which arises is how the level of BubR1/MAD2 proteins might 
influence c-MYC-induced chromosomal instability. Ectopic expression of MAD2 in 
MEFs leads to multiple chromosomal abnormalities like broken chromosomes, 
anaphase bridges, and whole-chromosome gains and losses (Hernando et al., 2004; 
Sotillo et al., 2007). This is in accordance with the previous observation that MAD2 
overexpression causes a hyperactive spindle checkpoint, which could result in the 
mitotic defects and chromosomal instability (Hernando et al., 2004). MAD2 
overexpression in in vivo model leads to a wide range of tumors in more than 50% of 
the mice and was shown to accelerate lymphomagenesis in the Eμ-myc mice (Sotillo 
et al., 2007). Recently, it has been shown that deregulation of the transcription factor 
E2F activates expression of MAD2 and delays mitotic progression (Hernando et al., 
2004). c-MYC presumably activates MAD2 expression independent of E2F as we 
observed induction of MAD2 by c-MYC in cells with knock-down of DP-1. However, 
E2F and c-MYC may act synergistically to activate MAD2 expression (Sears et al., 
1997). Hernando et al. proposed that the induction of MAD2 itself is the cause for CIN 
(Hernando et al., 2004). The analysis of c-MYC-induced genomic instability in DLD-1-
tTA-MYC and PJMMR1 cells did not reveal a requirement of MAD2 induction for c-
MYC-induced CIN. Moreover, experimental down-regulation of BubR1, which has a 
similar function as MAD2, also had no influence on c-MYC-induced CIN. In the 
experiments described here, partial down-regulation of BubR1 and MAD2 by stable 
shRNA expression prevents efficient c-MYC-dependent induction of these genes and 
leads to a minor increase of basal genomic instability level observed as elevation in 
micronuclei formation. Also no significant difference in abnormal chromatin formation 
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within mitotic progression was observed in time-lapse recordings when BubR1 or 
MAD2 knockdown and control populations were compared. These observations show 
that the induced expression of BubR1 and MAD2 mitotic checkpoint genes does not 
significantly participate in formation of chromosomal instability induced by c-MYC, but 
potentially plays a role in sensitizing the mitotic checkpoint. Aneuploidy caused by 
inactivation of BubR1 or MAD2 mitotic checkpoint genes has been implicated in 
tumorigenesis and suggests that these genes may function as tumor suppressors (van 
Deursen, 2007; Weaver et al., 2007). The reduction of both BubR1 and Mad2 proteins 
expression in mouse models results in chromosome missegregation. BubR1H/H 
(hypomorphic BubR1 mutation caused of BubR1 protein reduction reduction up 10% 
of normal level) mice exhibit increased susceptibility to tumours induced by 
carcinogenesis (Dai et al., 2004). BubR1+/-ApcMin/+ compound mutant mice develop 
colorectal cancer at a 10x higher rate than ApcMin/+ mice (Rao et al., 2005). As APC 
negatively regulates c-MYC (He et al,. Science) these tumors are presumably caused, 
at least in part, by deregulation of c-MYC. Cells from these mice showed premature 
separation of sister chromatids and enhanced genomic instability. In addition, germ 
line mutations in BubR1 have been linked to the rare cancer predisposition syndrome 
mosaic variegated aneuploidy (MVA) (Hanks et al., 2004; Matsuura et al., 2006). 
MAD2+/- mice develop lung tumors at high rates after long latencies (Dobles et al., 
2000). Furthermore, the current literature supports a function of MAD2 as a tumor 
suppressor as inactivating mutations have been identified in the MAD2 gene in 
bladder, breast and gastric cancer (Baek et al., 2005; Hernando et al., 2001; Percy et 
al., 2000).  
Current cellular models (DLD-1-tTA-MYC and PJMMR1 cells) involved in this 
study in principle do not exclude a link between MAD2 overexpression and 
chromosomal instability. One of the features of these systems is the rapid induction of 
c-MYC expression, both from CMV promoter, and the occurance of pronounced c-
MYC-induced phenotypes, including a rapid increase in cells with micronuclei 
representing CIN. The percentage of these cells in population rises up within first 4 
days of c-MYC induction and reached a plateau of 10-20% where it is balanced by an 
increasing rate of apoptosis. Further ectopic expression of c-MYC leads to a strong 
degree of instability, which is accompanied by massive apoptosis in these cells. 
Potentially, chromosomal instability induced by MAD2 (or/and BubR1) overexpression 
occurs in these c-MYC-inducible systems but is masked by c-MYC-induced apoptosis. 
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In this case would be interesting to modulate apoptosis rate by pan-caspase inhibitors 
which efficiently repress c-MYC-dependent cell death.  
 
6.4 c-MYC-induced apoptosis  
DLD-1-tTA-MYC cells, as others cells ectopically expressing c-MYC, show 
induction of apoptosis after induction of c-MYC. This apoptosis increases gradually. 
Two kinds of apoptosis were distinguished in time-lapse video of DLD-1-tTA-MYC 
cells after c-MYC activation. The first type of apoptosis represents spontaneous death 
of single cells and was not connected to mitotic progression. The second type, post-
mitotic apoptosis. represents the populations of cells synchronously dying after mitosis 
with chromatin condensation observed as late apoptotic events in both daughter 
progeny. The ratio between these two kinds of apoptosis was approximately 1:3 with 
the a maximum in the post-mitotic fraction 2 days after c-MYC induction. As DLD-1 
cells express a mutant p53 allele, post-mitotic apoptosis is p53-independent. The 
average time interval between the end of telophase and beginning of apoptotic 
chromatin condensation was around 4 hours after 2 days of c-MYC activation and 
drops down to 1-2 hours with a later time points (data not shown) probably due to 
increase of c-MYC-induced genomic instability formation as main reason for this. This 
average interval does not depend on the level of BubR1 or MAD2 protein expression. 
Itself, induction of post-mitotic apoptosis directly depend on c-MYC activation and 
reach 15 and 22 percent (23 out of 150 cells after 1 day and 49 out of 222 cells after 2 
days of c-MYC induction, respectively) of mitotic cells after 1 and 2 days of induction 
respectively (Figure 14, a) and has tendency for further elevation. Unfortunately the 
16x objective resolution applied for common time-lapse video acquisition did not 
allowed to observe smaller chromatin aberrations, which easily detectable with 
objectives with 40-60x magnification. Nevertheless, in cell populations undergoing 
post-mitotic apoptosis 35-40 percent (9 out of 23 and 17 out of 49 cells) contain 
detectible chromosomal aberrations in mitosis. As was described for chromosomal 
aberrations, the average length of mitosis of the cells undergoing post-mitotic 
apoptosis was 12 minutes more comparing to average mitotic cells without any 
aberrations or apoptosis. Almost whole population of cells with post-mitotic apoptosis 
has extended mitosis although some of the cells have completely normal mitotic 
progression. Interestingly, in time-lapse movie revealed BubR1 dependent formation 
of post-mitotic apoptosis in the population of mitotic cells after c-MYC activation. 
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BubR1 expression was controlled by shRNA mediated downregulation which prevents 
efficient BubR1 mRNA induction by c-MYC (Figure 7, b). After 48 hours of c-MYC 
expression I observed 4-5 % decrease of post-mitotic apoptosis in population of cells 
representing BubR1 downregulation in comparison to control (Figure 18, c). BubR1 
dependent apoptosis was described in literature (Shin et al., 2003). No significant 
difference was observed in the presence of MAD2 knockdown. In addition, DLD-1-tTA-
MYC cells undergoing massive apoptosis upon c-MYC activation in the presence of 
microtubule inhibitor nocodozol. All these observations show that post-mitotic 
apoptosis become induced before mitosis by c-MYC and could be modulated in 
mitosis, where induction of BubR1 spindle checkpoint serves tumor suppressive, 
proapoptotic function (Figure 28). 
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Figure 28 c-MYC activation alters progression through mitosis  
(a) c-MYC can directly activate genes involved in spindle checkpoint machinery or mitotic progression, 
depending on cell type and conditions leading to genome destabilization or apoptosis induction. (b) 
Indirect influence of c-MYC overactivation on mitotic progression might function through the modulation 
of spindle checkpoint machinery by generated DNA damage or active ATM signaling transmitted into 
mitosis. 
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6.5. All-in-one conditional microRNA expressing system 
A decade ago after discovery of RNA interference (RNAi) this mechanism has 
been implicated in a wide spectrum of genetic analysis and screens (Hannon, 2002; 
Meister and Tuschl, 2004; Paddison and Hannon, 2002; Paddison et al., 2004; Silva et 
al., 2004). The activation of the interference machinery involves the formation of ribo-
protein complexes guiding site-directed cleavage of the mRNA of interest by the anti-
sense ribo-sequence (Figure 4). The artificial delivery or vector-based expression of 
RNA templates in the cells allows effective and gentle manipulation of interference 
machinery. Despite simplicity and efficiency, the delivery of ssRNA or dsRNA itself by 
means of transfection approach is always limited by the efficacy of transfection and 
viability of introduced RNAs (Fewell and Schmitt, 2006). An alternative strategy is the 
expression of targeting shRNAs or miRNAs in cells achieved by vector-based 
expression. Such approaches allows its conditional regulation and co-expression of 
tracking proteins or selection markers. Furthermore, conditional regulation has a clear 
advantage of gentle physiological regulation in comparison to stable expression. 
However, the conditional systems published so far bear the necessary regulators on 
the separate plasmids, thereby complicating the generation of stable cell lines. 
Therefore our goal was to integrate all necessary components into the single plasmid 
to simplify procedures of cloning, delivery and integration of genetic elements allowing 
conditional regulation of miRNAs expression (Epanchintsev et al., 2006).   
For conditional regulation a bi-directional promoter bearing a tet-operon, which 
is based on minimal CMV-promoter region and tightly controlled by highly DOX-
sensitive reverse tetracycline trans-activator rtTA2S-M2 and tet repressor-KRAB fusion 
proteins (tTSKRAB) (Bornkamm et al., 2005). The system precisely responds to DOX 
level allowing expression of both a fluorescent protein and microRNA allele based on 
minimized version of mir30 transcript. In principle, the mir30 locus can be substituted 
by any other microRNA transcript, which broadens the flexibility of applications such 
as RNAi or translational inhibition (Figure 4). Additional features of the vector allow 
bacterial propagation and maintenance plasmid episomaly in the target cells (Li and 
Elledge, 2005). The Mir30 expression allele was constructed with possibility of either 
conventionally cloning of miRNA target sequences through the shuttle vector or magic 
recombination transfer strategy of miRNA cassettes from the microRNA library (Silva 
et al., 2005).  
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The functionality of the all-in-one pEMI system was establish using two distinct 
miRNA sequences targeted p53 tumor suppressor and MAD2, spindle checkpoint 
genes. Both systems show a fast response to the various DOX concentrations and 
represents tight off-state control. The depth of target protein knockdown gradually 
corresponds to the elevation of DOX concentration, has an effective down regulation 
at approximately 5 ng/ml of DOX and in case of MAD2 leads to almost complete 
protein depletion with already 100 ng/ml of DOX. The system also allows efficient 
knockdown restoration upon DOX withdrawl. The stability of pEMI integration was 
confirmed in different cell lines. U2OS and H1299 cell lines are susceptible to fast 
acquisition after transfection and selection procedures. Relatively long maintenance of 
the plasmid in the pool of cells last up to 4 weeks and allows preparation of 
conventionally long knockdown experiments. As well, the miRNA transcription from 
pEMI does not induce interferon pathway, confirming physiological compatibility of 
expression. 
The controlled activation of the knockdown may be useful in certain therapeutic 
regimes and prevent the potential toxicity or immunogenicity which has been 
discussed for therapeutic applications of ectopic RNA interference. As mentioned 
above the pEMI vector is compatible with recently generated microRNA libraries and 
will therefore presumably become a widely used tool for conditional RNA interference.  
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7. Summary 
 c-MYC is one of the major human oncogenes, however, the mechanisms 
involved in tumor initiation and development by c-MYC are not completely understood. 
One important function of c-MYC is the stimulation of G1/S-transition. However, the 
effects of c-MYC on G2/M progression and mitosis have not been characterized so far. 
The goal of the present study was to investigate the influence of c-MYC activation on 
the mitosis. Therefore, time-lapse microscopy of living cells was used to analyse 
mitotic progression after c-MYC activation. This analysis revealed a c-MYC-dependent 
extension of mitosis in prometaphase. This finding together with microarray analysis of 
c-MYC-regulated genes directed the attention of this work towards the spindle 
checkpoint genes. Two of them, MAD2 and BubR1, were characterized as direct c-
MYC target genes. Experimetall inactivation of MAD2 and BubR1 expression by RNA 
interference revealed that the c-MYC-induced lengthening of prometaphase is 
dependent on the induction of MAD2 and BubR1 by c-MYC. 
 Unexpectedly, further analysis did not reveal any influence of the c-MYC-
induced expression of MAD2 and BubR1 on c-MYC-induced chromosomal instability. 
These results therefore question the previously described mechanism by which the 
transcription factor E2F induces chromosomal instability. Furthermore, a synchronous 
postmitotic form of c-MYC-induced apoptosis was characterized. A minor contribution 
of the induction of BubR1 expression for type of apoptosis was detected. 
 Taken together these results show that deregulated expression of c-MYC, as it 
occurs in the majority of cancers, has drastic effects on the progression through  
mitosis: it delays mitosis in a MAD2- and BubR1-dependent manner. Furthermore, the 
effects of c-MYC on mitosis presumably provoke a cellular response which is 
manifested in post-mitotic apoptosis.  
 Recently, libraries of retroviral expression constructs encoding microRNAs 
which target most of the human and mouse genes became available. To allow the 
transfer of these microRNA cassettes into a new inducible, episomal expression 
system by homologous recombination, a new vector was generated and 
characterized. This system will allow the rapid functional and biochemical 
characterization of essential gene products by conditional RNA interference. 
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8. ABBREVIATIONS 
AML                           Acute lymphocytic leukemia 
APC                           Adenomatous polyposis coli 
APC/C                        Anaphase Promoting Complex or Cyclosome 
APS Ammonium peroxodisulfate 
ATM Ataxia telangiectasia mutated 
ATR                           ATM and Rad3-related 
BAX BCL2-associated X protein 
BCL-XL                      B-cell leukemia-x long 
BcL2                          B-cell leukemia 2 
BIM Bcl-2 interacting protein 
BRCA                        Breast cancer susceptibility gene 1/2 
Bub                            Budding uninhibited by benzimidazoles homolog 
BubR1                       Budding uninhibited by benzimidazoles 1 homolog beta; MAD3/BUB1-related protein kinase 
c MYC v-MYC avian myelocytomatosis viral oncogene homologue 
c-src                          Rous sarcoma viral oncogene homolog 
CAD Carbamoyl-phosphate synthetase 2 
CCD                           Charge-coupled device (camera) 
CDC                           Cell division cycle 
CDK Cyclin-dependent kinase 
cDNA Complementary DNA 
Cdt1                           Chromatin licensing and DNA replication factor 1 
CENP                         Centromere protein 
Chk                            Checkpoint kinase 
ChIP Chromatin immunoprecipitation 
CIN                             Chromosome instability 
CMV Cytomegalovirus (promoter) 
CUL1 Cullin 1 
Cy3 Cyanine 3 
dMYC                         Drosophila homolog of v-MYC 
DAPI 2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochloride 
DHFR                         Dihydrofolate reductase 
DLCL                         Diffuse large cell lymphoma 
DMEM Dulbecco's modified eagle medium 
DMSO Dimethylsulfoxide 
dNTP Deoxynucleotide triphosphate 
DP1 Deleted in polyposis 1 
DSB                           Double strand breaks 
dsRNA                       Double stranded RNA 
DTT        Dithiothreitol 
E-box Enhancer box 
E2F1 E2F transcription factor 1 
EBNA Epstein-Barr virus nuclear antigen 
E. coli Escherichia coli 
EDTA Ethylenediamine-tetraacetic acid 
EGTA Ethylene glycol-0,0'-bis (2-aminoethylether)-N,N,N',N'-tetraacetic acid 
FBS Foetal bovine serum 
G418 Geneticin® 
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GFP Green fluorescent protein 
HA Hemagglutinin 
H2AX                         H2A histone family, member X 
HBSS Hanks' balanced salt solution 
HNPCC                      Hereditary nonpolyposis colon cancer 
HPV                           Human papillomavirus 
HygB Hygromycin B 
ID2 Inhibitor of DNA binding 2 
IF Immunofluorescence 
Ig Immunoglobulin 
IPTG Isopropyl b-D-1-thiogalactopyranoside 
IRES Internal ribosome entry site 
IFIT1                          Interferon-induced protein with tetratricopeptide repeats 1 
LMYC Lung carcinoma-derived v-myc myelocytomatosis viral oncogene homologue                                                                                                       
LB Luria-Bertani 
MAD                           Mitotic arrest deficient-like 
MCM2 Minichromosome maintenance deficient  
Mdm2                        Mouse double minute 2 
MIN                            Microsatellite instability 
MIZ1 MYC-interacting zinc finger protein 1 
miRNA Micro RNA 
MLH                           MutL homolog         
MM                             Malignant melnoma 
MMR Mismatch repair  
Mos                            v-mos Moloney murine sarcoma viral oncogene homolog 
MSH MutS homologue  
NBL                           Neuroblastoma 
NMYC Neuroblastoma-derived v-myc myelocytomatosis viral oncogene homologue 
NP40 Nonidet-P40 
PCL                            Primary plasma cell leukemia 
p107 Retinoblastoma-like 1 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
pRB Retinoblastoma protein 
RAS Rat sarcoma viral oncogene homologue 
RNAi                          RNA interference 
ROS Reactive oxygen species 
RSV                           Rous sarcoma virus 
S-MYC MYC-like oncogene 
SAC                           Spindle assembly checkpoint 
SAGE Serial analysis of gene expression 
siRNA                        Small interfering RNA 
shRNA                       Small interfering RNA 
SCC                           Squamous cell carcinoma 
SCLC                         Small cell lung carcinoma 
SDS Sodium dodecyl sulfate 
tTA Tetracycline-controlled transactivator 
w/v Weight per volume 
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